U.S. patent application number 15/014694 was filed with the patent office on 2016-06-02 for methods for controlling the galactosylation profile of recombinantly-expressed proteins.
The applicant listed for this patent is AbbVie, Inc.. Invention is credited to Cornelia Bengea, Patrick Hossler, Lisa M. Rives.
Application Number | 20160152702 15/014694 |
Document ID | / |
Family ID | 46046346 |
Filed Date | 2016-06-02 |
United States Patent
Application |
20160152702 |
Kind Code |
A1 |
Bengea; Cornelia ; et
al. |
June 2, 2016 |
METHODS FOR CONTROLLING THE GALACTOSYLATION PROFILE OF
RECOMBINANTLY-EXPRESSED PROTEINS
Abstract
The present invention relates to methods for modulating the
glycosylation profile of recombinantly-expressed proteins. In
particular, the present invention relates to methods of controlling
the galactosylation profile of recombinantly-expressed proteins by
supplementing production medium, e.g., a hydrolysate-based or a
chemically defined medium, with manganese and/or D-galactose
Inventors: |
Bengea; Cornelia; (Auburn,
MA) ; Rives; Lisa M.; (Natick, MA) ; Hossler;
Patrick; (Westborough, MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
AbbVie, Inc. |
North Chicago |
IL |
US |
|
|
Family ID: |
46046346 |
Appl. No.: |
15/014694 |
Filed: |
February 3, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14619799 |
Feb 11, 2015 |
9255143 |
|
|
15014694 |
|
|
|
|
14493068 |
Sep 22, 2014 |
9090688 |
|
|
14619799 |
|
|
|
|
13457020 |
Apr 26, 2012 |
9062106 |
|
|
14493068 |
|
|
|
|
61479727 |
Apr 27, 2011 |
|
|
|
Current U.S.
Class: |
424/142.1 ;
435/69.6; 530/388.15 |
Current CPC
Class: |
C12N 2511/00 20130101;
C07K 2317/14 20130101; C12N 5/0018 20130101; C12N 2500/34 20130101;
C07K 16/241 20130101; C07K 2317/41 20130101; C07K 16/00 20130101;
C12P 21/005 20130101; C12N 2500/20 20130101; C07K 2317/21
20130101 |
International
Class: |
C07K 16/24 20060101
C07K016/24 |
Claims
1. A composition comprising an antibody comprising the heavy and
light chain variable domains of adalimumab, wherein less than 70%
of the total N-linked oligosaccharides present on said antibody are
of an agalactosyl fucosylated biantennary oligosaccharide form (sum
NGA2F+NGA2F-GlcNAc).
2. The composition of claim 1, wherein the antibody is
adalimumab.
3. The composition of claim 1, wherein 49-69% of the total N-linked
oligosaccharides present on said antibody are of an agalactosyl
fucosylated biantennary oligosaccharide form (sum
NGA2F+NGA2F-GlcNAc).
4. The composition of claim 1, wherein 55-65% of the total N-linked
oligosaccharides present on said antibody are of an agalactosyl
fucosylated biantennary oligosaccharide form (sum
NGA2F+NGA2F-GlcNAc).
5. The composition of claim 1, wherein 26-40% of the total N-linked
oligosaccharides present on said antibody are of a
galactose-containing fucosylated biantennary oligosaccharide form
(sum of NA1F+NA2F).
6. The composition of claim 1, wherein 35-44% of the total N-linked
oligosaccharides present on said antibody are of a
galactose-containing fucosylated biantennary oligosaccharide form
(sum of NA1F+NA2F).
7. The composition of claim 1, wherein 30-40% of the total N-linked
oligosaccharides present on said antibody are of a
galactose-containing fucosylated biantennary oligosaccharide form
(sum of NA1F+NA2F).
8. The composition of claim 1, wherein said antibody has been
produced by culturing a mammalian cell in a cell culture media
which has been supplemented with a manganese supplement and a
galactose supplement.
9. The composition of claim 8, wherein the cell culture media has
been supplemented with 0.2-100 .mu.M of a manganese supplement and
1-100 mM of a galactose supplement.
10. The composition of claim 8, wherein the cell culture media
comprises a hydrolysate based media or a chemically defined
media.
11. The composition of claim 8, wherein the mammalian cell is a CHO
cell or an NSO cell.
12. A pharmaceutical composition comprising the composition of
claim 1 and a pharmaceutically acceptable carrier.
13. The pharmaceutical composition of claim 12, wherein the
pharmaceutically acceptable carrier comprises a polyalcohol.
14. The pharmaceutical composition of claim 12, wherein the
pharmaceutically acceptable carrier comprises mannitol, sodium
chloride, sodium phosphate or polysorbate 80.
15. The pharmaceutical composition of claim 12, wherein the
pharmaceutical composition is suitable for parenteral
administration.
16. A composition comprising adalimumab, wherein less than 70% of
the total N-linked oligosaccharides present on said adalimumab are
of an agalactosyl fucosylated biantennary oligosaccharide form (sum
NGA2F+NGA2F-GlcNAc).
17. The composition of claim 16, wherein 49-69% of the total
N-linked oligosaccharides present on said adalimumab are of an
agalactosyl fucosylated biantennary oligosaccharide form (sum
NGA2F+NGA2F-GlcNAc).
18. The composition of claim 16, wherein 55-65% of the total
N-linked oligosaccharides present on said adalimumab are of an
agalactosyl fucosylated biantennary oligosaccharide form (sum
NGA2F+NGA2F-GlcNAc).
19. The composition of claim 16, wherein 26-40% of the total
N-linked oligosaccharides present on said adalimumab are of a
galactose-containing fucosylated biantennary oligosaccharide form
(sum of NA1F+NA2F).
20. The composition of claim 16, wherein 35-44% of the total
N-linked oligosaccharides present on said adalimumab are of a
galactose-containing fucosylated biantennary oligosaccharide form
(sum of NA1F+NA2F).
21. The composition of claim 16, wherein 30-40% of the total
N-linked oligosaccharides present on said adalimumab are of a
galactose-containing fucosylated biantennary oligosaccharide form
(sum of NA1F+NA2F).
22. The composition of claim 16, wherein said adalimumab has been
produced by culturing a mammalian cell in a cell culture media
which has been supplemented with a manganese supplement and a
galactose supplement.
23. The composition of claim 22, wherein the cell culture media has
been supplemented with 0.2-100 .mu.M of a manganese supplement and
1-100 mM of a galactose supplement.
24. The composition of claim 22, wherein the cell culture media
comprises a hydrolysate based media or a chemically defined
media.
25. The composition of claim 22, wherein the mammalian cell is a
CHO cell or an NSO cell.
26. A pharmaceutical composition comprising the composition of
claim 16 and a pharmaceutically acceptable carrier.
27. The pharmaceutical composition of claim 26, wherein the
pharmaceutically acceptable carrier comprises a polyalcohol.
28. The pharmaceutical composition of claim 26, wherein the
pharmaceutically acceptable carrier comprises mannitol, sodium
chloride, sodium phosphate or polysorbate 80.
29. The pharmaceutical composition of claim 26, wherein the
pharmaceutical composition further comprises polysorbate 80.
30. The pharmaceutical composition of claim 26, wherein the
pharmaceutical composition is suitable for parenteral
administration.
Description
RELATED APPLICATIONS
[0001] This application is a divisional application of U.S. patent
application Ser. No. 14/619,799; which is a continuation
application of U.S. patent application Ser. No. 14/493,068, filed
on Sep. 22, 2014, now U.S. Pat. No. 9,090,688, issued on Jul. 28,
2015; which is a divisional application of U.S. patent application
Ser. No. 13/457,020, filed on Apr. 26, 2012, now U.S. Pat. No.
9,062,106, issued on Jun. 23, 2015; which claims the benefit of
U.S. Provisional Application Ser. No. 61/479,727, filed on Apr. 27,
2011. The entire contents of each of the foregoing applications are
incorporated herein by reference.
1. INTRODUCTION
[0002] The present invention relates to methods for modulating the
glycosylation profile of recombinantly-expressed proteins. In
particular, the present invention relates to methods of controlling
the galactosylation profile of recombinantly-expressed proteins by
supplementing production media with manganese and/or galactose.
2. BACKGROUND OF THE INVENTION
[0003] Utilization of a particular type of production media, e.g.,
hydrolysate-based media or chemically defined media ("CD" or
"CDM"), for CHO cell cultures producing recombinant proteins can
enhance cell growth and target protein production. However,
recombinant proteins produced in different CD or hydrolysate-based
media can exhibit large differences in their product quality
profile. In certain instances, this variability can lead to
increases in the fraction of the agalactosyl fucosylated
biantennary oligosaccharides NGA2F+NGA2F-G1cNAc and decreases in
the fraction of galactose-containing fucosylated biantennary
oligosaccharides NA1F+NA2F. Shifts in the glycosylation profile of
recombinant proteins of this magnitude are significant as these
shifts may render the resulting production lots of the target
protein out of compliance with approved process specifications.
3. SUMMARY OF THE INVENTION
[0004] The present invention relates to methods for modulating the
glycosylation profile of recombinantly-expressed proteins. In
particular, the present invention relates to methods of controlling
the galactosylation profile of recombinantly-expressed proteins by
supplementing production media with manganese and/or galactose. In
certain embodiments the production media is a hydrolysate-based
media or a CD media.
[0005] In certain embodiments, the present invention is directed to
methods of controlling the galactosylation profile of
recombinantly-expressed antibody. In certain embodiments, the
recombinantly-expressed antibody is an anti-TNF.alpha. antibody. In
certain embodiments, the recombinantly-expressed anti-TNF.alpha.
antibody is adalimumab.
[0006] In certain embodiments, the present invention is directed to
methods of controlling the galactosylation profile of
recombinantly-expressed proteins by supplementing a production
medium, e.g., a hydrolysate-based or a CD medium, used in the
production of recombinantly-expressed proteins with manganese
and/or galactose. In certain embodiments, the manganese supplement
can take the form of any biologically-acceptable manganese salt,
for example, but not limited to, manganese (II) chloride. In
certain embodiments, the galactose supplement can take the form of
any biologically-acceptable galactose-containing compound, for
example, but not limited to, D-(+)-galactose.
[0007] In certain embodiments, the present invention is directed to
methods of controlling the galactosylation profile of
recombinantly-expressed proteins by supplementing a production
medium, e.g., a hydrolysate-based or a CD medium, used in the
production of recombinantly-expressed proteins with a sufficient
amount of manganese and/or a manganese-containing supplement to
achieve the following manganese concentrations in the production
media: at least about 0.1, at least about 0.2, at least about 0.5,
at least about 1.0, at least about 10, at least about 20, at least
about 25, at least about 40, at least about 50, at least about 60,
at least about 75, at least about 80, or at least about 100 .mu.M,
wherein that production media is used to dilute a supplement-free
cell culture growth media containing no supplement by a ratio of
about 1:4 or about 1:5 (supplement-free growth media: supplemented
production media). In certain embodiments, the present invention is
directed to methods of controlling the galactosylation profile of
recombinantly-expressed proteins by supplementing a production
medium, e.g., a hydrolysate-based or a CD medium, used in the
production of the recombinantly-expressed proteins with sufficient
galactose and/or galactose-containing supplement to achieve the
following galactose concentrations in the production media: at
least about 1, at least about 4, at least about 5, at least about
10, at least about 15, at least about 20, at least about 30, at
least about 40, at least about 60, or at least about 100 mM,
wherein that production media is used to dilute a supplement-free
cell culture growth media containing no supplement by a ratio of
about 1:4 or about 1:5 (supplement-free growth media: supplemented
production media).
[0008] In certain embodiments, the present invention is directed to
methods of controlling the galactosylation profile of
recombinantly-expressed proteins by supplementing a production
medium, e.g., a hydrolysate-based or a CD medium, used in the
production of recombinantly-expressed proteins with sufficient
manganese and/or a manganese-containing supplement and sufficient
galactose and/or galactose-containing supplement to achieve at
least about the following manganese (Mn) and galactose (Gal)
concentrations in the production media presented as Mn (.mu.M)/Gal
(mM): 0/1, 0/4, 0/5, 0/10, 0/15, 0/20, 0/30, 0/40, 0/60, 0/100,
0.1/0, 0.2/0, 0.5/0, 1.0/0, 10/0, 20/0, 25/0, 40/0, 50/0, 75/0,
80/0, 100/0, 0.2/1, 0.2/4, 0.2/30, 0.5/1, 0.5/4, 0.5/30, 10/10,
10/20, 10/40, 20/10, 20/20, 20/40, 25/15, 40/10, 40/20, 40/40,
40/100, 50/30, 60/20, 60/40, 60/100, 80/20, 80/40, 80/100, 100/20,
100/40, 100/100, wherein that production media is used to dilute a
supplement-free cell culture growth media containing no supplement
by a ratio of about 1:4 or about 1:5 (supplement-free growth media:
supplemented production media).
[0009] In certain embodiments, the present invention is directed to
methods of controlling the galactosylation profile of
recombinantly-expressed proteins by supplementing a production
medium, e.g., a hydrolysate-based or a CD medium, used in the
production of recombinantly-expressed proteins with sufficient
manganese and/or a manganese-containing supplement and sufficient
galactose and/or galactose-containing supplement to achieve at
least about the following manganese (Mn) and galactose (Gal)
concentrations in the production media presented as Mn (.mu.M)/Gal
(mM): 0.2/1, 0.2/4, 0.2/30, 0.5/1, 0.5/4, 0.5/30, 10/10, 10/20,
10/40, 20/10, 20/20, 20/40, 25/15, 40/10, 40/20, 40/40, 40/100,
50/30, 60/20, 60/40, 60/100, 80/20, 80/40, 80/100, 100/20, 100/40,
100/100, wherein that production media is used to dilute a
supplement-free cell culture growth media containing no supplement
by a ratio of about 1:4 or about 1:5 (supplement-free growth media:
supplemented production media).
4. BRIEF DESCRIPTION OF THE FIGURES
[0010] FIG. 1A depicts the culture growth of adalimumab-producing
CHO cell line in CDM GIA-1 in batch shake flasks. FIG. 1B depicts
the viability of adalimumab-producing CHO cell line in CDM GIA-1 in
batch shake flasks. FIG. 1C depicts the normalized titer of
adalimumab-producing CHO cell line in CDM GIA-1 in batch shake
flasks.
[0011] FIG. 2A depicts the culture growth of adalimumab-producing
CHO cell line in CDM GIA-1 in fed-batch 3 L bioreactors. FIG. 2B
depicts the viability of adalimumab-producing CHO cell line in CDM
GIA-1 in fed-batch 3 L bioreactors. FIG. 2C depicts the normalized
titer of adalimumab-producing CHO cell line in CDM GIA-1 in
fed-batch 3 L bioreactors.
[0012] FIG. 3A depicts the galactosylation profile
(NGA2F+NGA2F-GlcNac) of adalimumab in CHO cell line in CDM GIA-1 in
batch shake flasks. FIG. 3B depicts the galactosylation profile
(NA1F+NA2F) of adalimumab in CHO cell line in CDM GIA-1 in batch
shake flasks.
[0013] FIG. 4 depicts the percentage galactosylation change of
adalimumab in CDM GIA-1 in batch shake flasks relative to
control.
[0014] FIG. 5 summarizes the effect of manganese and/or galactose
addition to CDM GIA-1 on galactosylation of adalimumab relative to
control in CHO cell line.
[0015] FIG. 6A depicts the galactosylation profile
(NGA2F+NGA2F-GlcNac) of adalimumab in CHO cell line in CDM GIA-1 in
fed-batch 3 L bioreactors. FIG. 6B depicts the galactosylation
profile (NA1F+NA2F) of adalimumab in CHO cell line in CDM GIA-1 in
fed-batch 3 L bioreactors.
[0016] FIG. 7A depicts the culture growth of CHO cell line in CDM
HyClone CDM4CHO in batch shake flasks. FIG. 7B depicts the
viability of CHO cell line in CDM HyClone CDM4CHO in batch shake
flasks.
[0017] FIG. 8A depicts the galactosylation profile
(NGA2F+NGA2F-GlcNac) of adalimumab in CHO cell line in CDM HyClone
CDM4CHO in batch shake flasks. FIG. 8B depicts the galactosylation
profile (NA1F+NA2F) of adalimumab in CHO cell line in CDM HyClone
CDM4CHO in batch shake flasks.
[0018] FIG. 9 summarizes the effect of manganese and/or galactose
addition to CDM HyClone CDM4CHO on galactosylation of adalimumab
relative to control in CHO cell line.
[0019] FIG. 10A depicts the culture growth of CHO cell line in
hydrolysate media in batch shake flasks. FIG. 10B depicts the
viability of CHO cell line in hydrolysate media in batch shake
flasks.
[0020] FIG. 11A depicts the galactosylation profile
(NGA2F+NGA2F-GlcNac) of adalimumab in CHO cell line in hydrolysate
media in batch shake flasks. FIG. 11B depicts the galactosylation
profile (NA1F+NA2F) of adalimumab in CHO cell line in hydrolysate
media in batch shake flasks.
[0021] FIG. 12 summarizes the effect of manganese and/or galactose
addition to hydrolysate media on galactosylation of adalimumab
relative to control in CHO cell line.
[0022] FIG. 13A depicts the culture growth of adalimumab-producing
CHO cell line #2 in CDM GIA-1 in batch shake flasks. FIG. 13B
depicts the viability of adalimumab-producing CHO cell line #2 in
CDM GIA-1 in batch shake flasks.
[0023] FIG. 14A depicts the galactosylation profile
(NGA2F+NGA2F-GlcNac) of adalimumab in CHO cell line #2 in CDM GIA-1
in batch shake flasks. FIG. 14B depicts the galactosylation profile
(NA1F+NA2F) of adalimumab in CHO cell line #2 in CDM GIA-1 in batch
shake flasks.
[0024] FIG. 15 summarizes the effect of manganese and/or galactose
addition to CDM GIA-1 on galactosylation of adalimumab relative to
control in CHO cell line #2.
[0025] FIG. 16A depicts the culture growth of adalimumab-producing
CHO cell line #3 in CDM GIA-1 in fed-batch 3 L bioreactors. FIG.
16B depicts the viability of adalimumab-producing CHO cell line #3
in CDM GIA-1 in fed-batch 3 L bioreactors. FIG. 16C depicts the
normalized titer of adalimumab-producing CHO cell line #3 in CDM
GIA-1 in fed-batch 3 L bioreactors.
[0026] FIG. 17A depicts the galactosylation profile
(NGA2F+NGA2F-GlcNac) of adalimumab in CHO cell line #3 in CDM GIA-1
in fed-batch 3 L bioreactors. FIG. 17B depicts the galactosylation
profile (NA1F+NA2F) of adalimumab in CHO cell line #3 in CDM GIA-1
in fed-batch 3 L bioreactors.
[0027] FIG. 18 summarizes the effect of manganese and/or galactose
addition to CDM GIA-1 on galactosylation of adalimumab relative to
control in CHO cell line #3.
[0028] FIG. 19A depicts the culture growth of adalimumab-producing
NSO cell line in CDM PFBM-3/PFFM-4 fed-batch shake flasks. FIG. 19B
depicts the viability of adalimumab-producing NSO cell line in CDM
PFBM-3/PFFM-4 fed-batch shake flasks. FIG. 19C depicts the
normalized titer of adalimumab-producing NSO cell line in CDM
PFBM-3/PFFM-4 fed-batch shake flasks.
[0029] FIG. 20A depicts the galactosylation profile
(NGA2F+NGA2F-GlcNac) of adalimumab in NSO cell line in CDM
PFBM-3/PFFM-4 fed-batch shake flasks. FIG. 20B depicts the
galactosylation profile (NA1F+NA2F) of adalimumab in NSO cell line
in CDM PFBM-3/PFFM-4 fed-batch shake flasks.
[0030] FIG. 21 summarizes the effect of manganese and/or galactose
addition to CDM PFBM-3/PFFM-4 on galactosylation of adalimumab
relative to control in NSO cell line.
[0031] FIG. 22A depicts the culture growth of CHO cell line
producing mAb #1 in CDM GIA-1 in batch shake flasks. FIG. 22B
depicts the viability of CHO cell line producing mAb #1 in CDM
GIA-1 in batch shake flasks.
[0032] FIG. 23A depicts the galactosylation profile
(NGA2F+NGA2F-GlcNAc) of mAb #1 in CDM GIA-1 in batch shake flasks.
FIG. 23B depicts the galactosylation profile (NA1F+NA2F) of mAb #1
in CDM GIA-1 in batch shake flasks.
[0033] FIG. 24 summarizes the effect of manganese and/or galactose
addition to CDM GIA-1 on galactosylation of mAb #1 relative to
control.
[0034] FIG. 25A depicts the culture growth of CHO cell line
producing mAb #2 in CDM GIA-1 in fed-batch 3 L bioreactors. FIG.
25B depicts the viability of CHO cell line producing mAb #2 in CDM
GIA-1 in fed-batch 3 L bioreactors. FIG. 25C depicts the normalized
titer of CHO cell line producing mAb #2 in CDM GIA-1 in fed-batch 3
L bioreactors.
[0035] FIG. 26A depicts the glycosylation profile
(NGA2F+NGA2F-GlcNAc) of mAb #2 in CDM GIA-1 in fed-batch 3 L
bioreactors. FIG. 26B depicts the glycosylation profile (NA1F+NA2F)
of mAb #2 in CDM GIA-1 in fed-batch 3 L bioreactors.
[0036] FIG. 27 summarizes the effect of manganese and/or galactose
addition to CDM GIA-1 on galactosylation of mAb #2 relative to
control.
5. DETAILED DESCRIPTION OF THE INVENTION
[0037] The present invention relates to methods modulating the
glycosylation profile of recombinantly-expressed proteins. In
particular, the present invention relates to methods of controlling
(e.g., modulating) the galactosylation profile of
recombinantly-expressed proteins by supplementing production
medium, e.g., a hydrolysate-based or a CD medium, with manganese
and/or galactose. For example, but not by way of limitation, the
present invention demonstrates that supplementation of particular
ranges of manganese and/or galactose concentrations to chemically
defined media can be used to fine-tune the galactosylation profile
of monoclonal antibodies produced in CHO and NSO cell lines.
Similarly, supplementation of galactose alone to hydrolysate-based
media is effective to modulate the galactosylation profile of the
monoclonal antibody adalimumab produced in a CHO cell line in a
concentration dependent manner. In view of such findings, the
methods disclosed herein can be used to modulate the galactose
content of recombinant proteins by controlling the amounts of
manganese and/or galactose present in cell culture media. The
studies described herein have also established that the changes in
the galactosylation profiles obtained via implementation of the
methods of the present invention are not only scale (1.5 L vs. 200
mL) and process independent (fed-batch in controlled bioreactor
environment vs. batch in shake flasks), but also that no
significant impact on culture growth and productivity is observed
for most conditions studied.
[0038] A terminal galactose is added to NGA2F by
.beta.-galactosyltransferase enzyme in the presence of manganese
chloride, to produce NA1F (in the case of an addition of a single
terminal galactose) or NA2F (in the case of an addition of two
terminal galactose molecules). This galactosyltransferase-mediated
reaction employs UDP-galactose as the sugar substrate and Mn.sup.2+
as a cofactor for galactosyltransferase. Thus, without being bound
by theory, it is believed that a change in protein homogeneity
taking the form of an increase in the fraction of N-linked
oligosaccharide NGA2F and a decrease in the fraction of NA1F+NA2F
N-linked oligosaccharides could be caused by either an insufficient
amount of the substrate (UDP-galactose), the cofactor for
galactosyltransferase (Mn.sup.2+), or both.
[0039] In certain embodiments, the present invention is directed to
methods of controlling the galactosylation profile of
recombinantly-expressed antibody. In certain embodiments, the
recombinantly-expressed antibody is an anti-TNF.alpha. antibody. In
certain embodiments, the recombinantly-expressed anti-TNF.alpha.
antibody is adalimumab.
[0040] In certain embodiments, the present invention is directed to
methods of controlling the galactosylation profile of
recombinantly-expressed proteins by supplementing a production
medium, e.g., a hydrolysate-based or a CD medium, used in the
production of recombinantly-expressed proteins with manganese
and/or galactose. In certain embodiments, the manganese supplement
can take the form of any biologically-acceptable manganese salt,
for example, but not limited to, manganese (II) chloride. In
certain embodiments, the galactose supplement can take the form of
any biologically-acceptable galactose-containing compound, for
example, but not limited to, D-(+)-galactose.
[0041] In certain embodiments, the present invention is directed to
methods of controlling the galactosylation profile of
recombinantly-expressed proteins by supplementing a production
medium, e.g., a hydrolysate-based or a CD medium, used in the
production of recombinantly-expressed proteins with a sufficient
amount of manganese and/or a manganese-containing supplement to
achieve at least about the following manganese concentrations in
the production media: at least about 0.1, at least about 0.2, at
least about 0.5, at least about 1.0, at least about 10, at least
about 20, at least about 25, at least about 40, at least about 50,
at least about 60, at least about 75, at least about 80, or at
least about 100 .mu.M, wherein that production media is used to
dilute a supplement-free cell culture growth media containing no
supplement by a ratio of about 1:4 or about 1:5 (supplement-free
growth media: supplemented production media). In certain
embodiments, the present invention is directed to methods of
controlling the galactosylation profile of recombinantly-expressed
proteins by supplementing a production medium, e.g., a
hydrolysate-based or a CD medium, used in the production of
recombinantly-expressed proteins with sufficient galactose and/or
galactose-containing supplement to achieve at least about the
following galactose concentrations in the production media: at
least about 1, at least about 4, at least about 5, at least about
10, at least about 15, at least about 20, at least about 30, at
least about 40, at least about 60, or at least about 100 mM,
wherein that production media is used to dilute a supplement-free
cell culture growth media containing no supplement by a ratio of
about 1:4 or about 1:5 (supplement-free growth media: supplemented
production media).
[0042] In certain embodiments, the present invention is directed to
methods of controlling the galactosylation profile of
recombinantly-expressed proteins by supplementing a production
medium, e.g., a hydrolysate-based or a CD medium, used in the
production ofrecombinantly-expressed proteins with sufficient
manganese and/or a manganese-containing supplement and sufficient
galactose and/or galactose-containing supplement to achieve at
least about the following manganese (Mn) and galactose (Gal)
concentrations in the production media presented as Mn (.mu.M)/Gal
(mM): 0/1, 0/4, 0/5, 0/10, 0/15, 0/20, 0/30, 0/40, 0/60, 0/100,
0.1/0, 0.2/0, 0.5/0, 1.0/0, 10/0, 20/0, 25/0, 40/0, 50/0, 75/0,
80/0, 100/0, 0.2/1, 0.2/4, 0.2/30, 0.5/1, 0.5/4, 0.5/30, 10/10,
10/20, 10/40, 20/10, 20/20, 20/40, 25/15, 40/10, 40/20, 40/40,
40/100, 50/30, 60/20, 60/40, 60/100, 80/20, 80/40, 80/100, 100/20,
100/40, 100/100, wherein that production media is used to dilute a
supplement-free cell culture growth media containing no supplement
by a ratio of about 1:4 or about 1:5 (supplement-free growth media:
supplemented production media).
[0043] In certain embodiments, the present invention is directed to
methods of controlling the galactosylation profile of
recombinantly-expressed proteins by supplementing a production
medium, e.g., a hydrolysate-based or a CD medium, used in the
production of recombinantly-expressed proteins with sufficient
manganese and/or a manganese-containing supplement and sufficient
galactose and/or galactose-containing supplement to achieve at
least about the following manganese (Mn) and galactose (Gal)
concentrations in the production media presented as Mn (.mu.M)/Gal
(mM): 0.2/1, 0.2/4, 0.2/30, 0.5/1, 0.5/4, 0.5/30, 10/10, 10/20,
10/40, 20/10, 20/20, 20/40, 25/15, 40/10, 40/20, 40/40, 40/100,
50/30, 60/20, 60/40, 60/100, 80/20, 80/40, 80/100, 100/20, 100/40,
100/100, wherein that production media is used to dilute a
supplement-free cell culture growth media containing no supplement
by a ratio of about 1:4 or about 1:5 (supplement-free growth media:
supplemented production media).
[0044] In certain embodiments, the production medium, e.g., a
hydrolysate-based or a CD medium, used in the production of a
recombinantly-expressed protein is supplemented with manganese and
not galactose. For the shake flasks studies in Example 1, but not
by way of limitation, addition of manganese and not galactose to
production IVGN CDM GIA-1 lowered the NGA2F+NGA2F-GlcNac sum by 6%
to 9% and increased the NA1F+NA2F sum by 8% to 9% (FIGS. 3, 4, and
5). No further increase in manganese concentration was explored in
the experimental design due to the growth inhibition observed at
about 100 .mu.M.
[0045] In certain embodiments, the production medium, e.g., a
hydrolysate-based or a CD medium, used in the production of a
recombinantly-expressed protein is supplemented with galactose and
not manganese. For the shake flasks studies in Example 1, but not
by way of limitation, addition of galactose only to production IVGN
CDM GIA-1 lowered the NGA2F+NGA2F-GlcNac sum by 3% to 7% and
increased NA1F+NA2F by 3% to 7% (FIGS. 3, 4, and 5). These findings
indicate that a manganese concentration of about 100 .mu.M and a
galactose concentration of about 100 mM represent the maximum range
of interest for this Example 1.
[0046] In certain embodiments, the production medium, e.g., a
hydrolysate-based media or a CD media, used in the production of a
recombinantly-expressed protein is supplemented with both manganese
and galactose. For example, but not by way of limitation, the
studies outlined in Example 1 indicate that the addition of
combinations of manganese and galactose to production IVGN CDM
GIA-1 resulted in a significant decrease in the NGA2F+NGA2F-GlcNac
sum of 11% to 26% and a corresponding significant increase in the
NA1F+NA2F sum of 13% to 23% as compared to the control condition
where no manganese or galactose were added to the production media
(FIGS. 3, 4, and 5). The effect on modulation of galactosylation of
adalimumab in production IVGN CDM GIA-1 with the combined addition
of manganese chloride and galactose was synergistic. In particular,
the combined addition of manganese chloride and galactose decreased
the NGA2F+NGA2F-GlcNac sum and increased the NA1F+NA2F sum by a
larger percentage than by adding manganese or galactose alone and
summing up their individual effects. For example, but not by way of
limitation, addition of 40 .mu.M manganese chloride alone reduced
the NGA2F sum by 6%, and addition of 40 mM galactose alone
decreased the NGA2F+NGA2F-GlcNac sum by 6%. However, the combined
addition of manganese chloride and galactose at these same
concentrations (i.e. 40 .mu.M manganese+40 mM galactose) led to an
18% reduction in the NGA2F+NGA2F-GlcNac sum, 6% higher than their
combined individual contributions to the reduction of the
NGA2F+NGA2F-GlcNac sum. We define this effect as being synergistic
and maintain this definition throughout the invention. The largest
percent decrease in the NGA2F+NGA2F-GlcNac sum of approximately 26%
was observed with the combined addition of 100 .mu.M manganese
chloride and 100 mM galactose. The largest percent increase in the
NA1F+NA2F sum of approximately 23% was recorded with the combined
addition of 60 .mu.M manganese chloride and 100 mM galactose.
[0047] For the fed-batch bioreactor study described in Example 1,
two manganese chloride and galactose combinations were studied and
the results indicate that the decrease in the NGA2F+NGA2F-GlcNac
sum and the corresponding increase in the NA1F+NA2F sum was scale
(1.5 L vs. 200 mL) and process independent (fed-batch in controlled
bioreactor environment vs. batch in shake flasks). For example, but
not by way of limitation, the combined addition of 40 .mu.M
manganese chloride and 20 mM galactose to both production basal CDM
GIA-1 and feed CDM JCL-5 decreased the NGA2F+NGA2F-GlcNac sum by
26% and increased the NA2F+NA2F sum by 27% compared to the control
cultures (FIG. 6). A further increase in the galactose
concentration to 40 mM in addition to manganese supplementation at
40 .mu.M concentration resulted in an additional 3% decrease in the
NGA2F+NGA2F-GlcNac sum, and a corresponding 3% increase in the
NA1F+NA2F sum
[0048] In certain embodiments, the present invention is directed to
the supplementation of CD media used in the production of a
recombinantly-expressed protein with galactose and/or manganese.
That such supplementation is effective across distinct CD media is
evidenced by the results outlined in Example 2. Specifically,
Example 2 results indicate that the addition of manganese chloride
alone within the range of 0 to 40 .mu.M to production CDM HyClone
CDM4CHO decreased the NGA2F+NGA2F-GlcNac sum by a maximum of 5% in
a concentration dependent manner (FIG. 8). A comparable maximum
increase of 4% in the NA1F+NA2F sum was also achieved. Addition of
galactose alone up to a maximum concentration of 40 mM yielded a 6%
maximum decrease in the NGA2F+NGA2F-GlcNac sum and a corresponding
6% increase in the NA1F+NA2F sum. Modulation of galactosylation was
also observed in production CDM HyClone CDM4CHO cultures
supplemented with both manganese chloride and galactose. An
additive effect was observed in cultures supplemented with both
manganese chloride and galactose. The combined addition of
manganese chloride and galactose decreased the NGA2F+NGA2F-GlcNac
sum and increased the NA1F+NA2F sum by a comparable percentage as
when manganese or galactose were added alone and their individual
effects were summed up (FIG. 9). For example, but not by way of
limitation, addition of 40 .mu.M manganese chloride alone reduced
the NGA2F+NGA2F-GlcNac sum by 5%, and addition of 40 mM galactose
alone decreased the NGA2F sum by 6%. The combined addition of
manganese chloride and galactose at these same concentrations (i.e.
40 .mu.M manganese+40 mM galactose) led to a 12% reduction in the
NGA2F+NGA2F-GlcNac sum. We define this effect as being additive and
maintain this definition throughout the invention. The highest
percentage decrease in the NGA2F sum of 12% and the corresponding
11% increase in the NA1F+NA2F sum was observed for the culture
supplemented with 40 .mu.M manganese chloride and 40 mM
galactose.
[0049] In certain embodiments, the present invention is directed to
the supplementation of a hydrolysate-based media used in the
production of a recombinantly-expressed protein with galactose
and/or manganese. For example, as outlined in Example 3, the
addition of manganese chloride alone within the range of 0 to 40
.mu.M to hydrolysate-based production media decreased the
NGA2F+NGA2F-GlcNac sum by approximately 1%, although that change is
within the oligosaccharide assay variability (FIG. 11). The
addition of galactose alone up to a maximum concentration of 40 mM
yielded a maximum decrease of 4% in the NGA2F+NGA2F-GlcNac sum and
a corresponding 4% maximum increase in the NA1F+NA2F sum. Such
oligosaccharide profile changes achieved with the addition of
galactose alone are comparable to the changes recorded when
combinations of galactose and manganese chloride were added to the
hydrolysate-based media. For example, the combined addition of
manganese chloride ranging from 0 to 40 .mu.M and galactose ranging
from 0 to 40 mM to hydrolysate-based media led to an approximate 5%
maximum decrease in the NGA2F+NGA2F-GlcNac sum and a corresponding
3% increase in the NA1F+NA2F sum (FIG. 12). The highest percentage
decrease of 5% in the NGA2F+NGA2F-GlcNac sum and the corresponding
4% increase in the NA1F+NA2F sum was observed for the culture
supplemented with 40 mM galactose and either 20 .mu.M or 40 .mu.M
manganese chloride.
[0050] The compositions and methods of the present invention also
find use across distinct cell lines. For example, but not by way of
limitation, the study described in Example 4 illustrates that the
supplementation of a CD media, GIA-1, with galactose and/or
manganese is effective to modulate galactosylation of adalimumab
produced using a CHO cell line distinct from that employed in
Examples 1-3. For example, but not by way of limitation, when using
this alternative cell line, the addition of manganese chloride
alone within the range of 0 to 20 .mu.M to production CDM GIA-1
decreased the NGA2F+NGA2F-GlcNac sum in a concentration dependent
manner and increased the NA1F+NA2F sum by approximately the same
percentage. A maximum decrease of 22% in the NGA2F+NGA2F-GlcNac sum
and a maximum corresponding increase of 23% in the NA1F+NA2F sum
was observed with the addition of 20 .mu.M manganese chloride (FIG.
14). Similarly, a concentration dependent decrease in the
NGA2F+NGA2F-GlcNac sum and a corresponding increase in the
NA1F+NA2F sum was observed with the addition of galactose alone in
the range of 0 to 20 mM. A maximum decrease of 9% in the
NGA2F+NGA2F-GlcNac sum and a corresponding maximum increase of 10%
in the NA1F+NA2F sum was observed with the addition of 20 mM
galactose. Similarly, an additive effect was observed for the
oligosaccharide profiles of adalimumab produced in cultures
supplemented with the combined addition of manganese chloride and
galactose to GIA-1 media (FIG. 15). For example, but not by way of
limitation, addition of 10 .mu.M manganese chloride alone reduced
the NGA2F+NGA2F-GlcNAc sum by 18%, and addition of 10 mM galactose
alone decreased the NGA2F+NGA2F-GlcNAc sum by 6%. The combined
addition of manganese chloride and galactose at these same
concentrations led to a 24% reduction in the NGA2F+NGA2F-GlcNac
sum. The highest percentage decrease of 35% in the
NGA2F+NGA2F-GlcNAc sum and the corresponding increase of 37% in the
NA1F+NA2F sum were observed for the culture supplemented with 40
.mu.M manganese chloride and 20 mM galactose.
[0051] That the compositions and methods of the present invention
also find use across distinct cell lines is further reinforced by
the results of Example 5, which employs a third
adalimumab-producing cell line that is distinct from either of the
adalimumab-producing cell lines of Examples 1-4. For example, but
not by way of limitation, when using this third cell line, the
addition of manganese chloride alone within the range of 0 to 1
.mu.M to production CDM GIA-1 decreased the NGA2F+NGA2F-GlcNAc sum
in a concentration dependent manner and increased the NA1F+NA2F sum
by approximately the same percentage. A maximum decrease of 26% in
the NGA2F+NGA2F-GlcNAc and a corresponding increase of 28% in the
NA1F+NA2F oligosaccharides were observed with the addition of 1
.mu.M manganese chloride (FIG. 17). The addition of galactose alone
at 30 mM concentration to production CDM GIA-1 decreased the
NGA2F+NGA2F-GlcNAc sum by 4% and increased the NA1F+NA2F sum by 3%.
Furthermore, when manganese chloride and galactose were
supplemented together into the production basal and feed media, the
results demonstrated a synergistic benefit towards the decrease in
the NGA2F+NGA2F-GlcNAc and the increase in the NA1F+NA2F
oligosaccharides which is consistent with the results demonstrated
in Example 1 (FIG. 18). For example, but not by way of limitation,
at 0.2 .mu.M manganese chloride plus 30 mM galactose the observed
25% decrease in the NGA2F+NGA2F-GlcNAc sum was 6% more than the sum
of the decrease observed with the addition of 0.2 .mu.M manganese
chloride alone (15%) and that of 30 mM galactose alone (4%).
Similarly, the resulting 24% increase in the NA1F+NA2F sum was more
than the sum of the increase observed with the addition of 0.2
.mu.M manganese chloride alone (16%) and that of 30 mM galactose
alone (3%). The combined supplementation of 0.5 .mu.M manganese
chloride+30 mM galactose also demonstrated a synergistic effect on
the galactosylation profile of adalimumab produced in this third
cell line. A maximum decrease compared to the control condition of
34% in the NGA2F+NGA2F-GlcNac and a corresponding 34% maximum
increase in the NA1F+NA2F oligosaccharides was observed with the
combined addition of 0.5 .mu.M manganese chloride and 30 mM
galactose to chemically defined GIA-1 media.
[0052] That the compositions and methods of the present invention
also find use across distinct types of cell lines is further
reinforced by the results of Example 6, which employs a fourth
adalimumab-producing cell line that is distinct from the
adalimumab-producing cell lines of Examples 1-5, in that it is an
NSO cell line. For example, but not by way of limitation, when
using this NSO cell line, the addition of manganese chloride alone
within the range of 0 to 0.5 .mu.M to production CDM PFBM-3/PFFM-4
decreased the NGA2F+NGA2F-GlcNac sum in a concentration dependent
manner and increased the NA1F+NA2F sum by approximately the same
percentage. A maximum decrease of 18% in the NGA2F+NGA2F-GlcNac sum
and a corresponding increase of 20% in the NA1F+NA2F sum were
observed with the addition of 0.5 .mu.M manganese chloride (FIG.
20). However, manganese doses greater than 0.5 .mu.M were not
explored further due to cytotoxicity effects. Similarly, a
concentration dependent decrease in the NGA2F+NGA2F-GlcNac sum and
a corresponding increase in the NA1F+NA2F sum were observed with
the addition of galactose alone in the range of 0 to 10 mM to
production CDM PFBM-3/PFFM-4. A maximum decrease of 14% in the
NGA2F+NGA2F-GlcNac sum and a corresponding increase of 15% in the
NA1F+NA2F sum was observed with the addition of 10 mM galactose. In
addition, the effect on modulation of galactosylation of adalimumab
produced in a NSO cell line in production CDM PFBM-3/PFFM-4
supplemented with manganese chloride and galactose was synergistic
(FIG. 21). For example, but not by way of limitation, addition of
0.2 .mu.M manganese chloride alone reduced the NGA2F+NGA2F-GlcNac
sum by 12%, and addition of 4 mM galactose alone decreased the
NGA2F+NGA2F-GlcNac sum by 2%. However, the combined addition of
manganese chloride and galactose at these same concentrations (i.e.
0.2 .mu.M manganese+4 mM galactose) led to a 19% reduction in the
NGA2F+NGA2F-GlcNac sum, 5% higher than their combined individual
contributions. A maximum decrease of .about.26% in the
NGA2F+NGA2F-GlcNac sum and a corresponding 28% increase in the
NA1F+NA2F sum were observed with the combined addition of 0.5 .mu.M
manganese chloride and 4 mM galactose.
[0053] The compositions and methods of the present invention also
find use in the production of diverse antibodies, as evidenced by
the results of Example 7, which employs a CHO cell line that
produced an antibody distinct from adalimumab. For example, but not
by way of limitation, when producing this antibody distinct from
adalimumab, the addition of manganese chloride alone within the
range of 0 to 40 .mu.M to production CDM GIA-1 decreased the
NGA2F+NGA2F-GlcNac sum by a maximum of 26% (FIG. 23). A comparable
maximum increase of 27% in the NA1F+NA2F sum was also achieved.
Addition of galactose alone up to a maximum concentration of 40 mM
yielded a maximum decrease of 12% in the NGA2F+NGA2F-GlcNac sum and
a corresponding 13% maximum increase in the NA1F+NA2F sum in a
concentration dependent manner. In addition, the combined addition
of galactose and manganese chloride to production CDM GIA-1
resulted in a greater percent reduction in the NGA2F+NGA2F-GlcNac
sum and, correspondingly, a greater percent increase in the
NA1F+NA2F sum as compared to the addition of either component alone
(FIG. 24). For example, but not by way of limitation, the addition
of 40 .mu.M manganese chloride alone reduced the NGA2F+NGA2F-GlcNac
sum by 20%, and the addition of 40 mM galactose alone decreased the
NGA2F+NGA2F-GlcNac sum by 12%. However, the combined addition of
manganese chloride and galactose at these same concentrations (i.e.
40 .mu.M manganese+40 mM galactose) led to a 27% decrease in the
NGA2F+NGA2F-GlcNac sum. The highest percentage decrease of 32% in
the NGA2F+NGA2F-GlcNac sum and the corresponding increase of 30% in
the NA1F+NA2F sum were observed for the culture supplemented with
20 .mu.M manganese chloride and 20 mM galactose.
[0054] That the compositions and methods of the present invention
also find use when producing diverse antibodies is further
reinforced by the results of Example 8, which employs a CHO cell
line producing an antibody distinct from both adalimumab and the
antibody of Example 7. For example, but not by way of limitation,
when producing this third antibody, the addition of manganese
chloride alone in the range of 0 to 75 .mu.M to production CDM
GIA-1 decreased the NGA2F+NGA2F-GlcNac sum by a maximum of 18%
(FIG. 26). A comparable maximum increase of 16% in the NA1F+NA2F
sum was also achieved. Addition of galactose alone up to a maximum
concentration of 60 mM yielded a maximum decrease of 12% in the
NGA2F+NGA2F-GlcNac sum and a corresponding 11% maximum increase in
the NA1F+NA2F sum. In addition, when manganese chloride and
galactose were supplemented together into the basal and feed media,
the results demonstrated at least an additive effect and sometimes
a synergistic effect towards the decrease in the NGA2F+NGA2F-GlcNAc
sum and the increase in the NA1F+NA2F sum (FIG. 27). The
synergistic effect was observed for the condition supplemented with
25 .mu.M manganese chloride and 15 mM galactose. The observed 22%
decrease in the NGA2F+NGA2F-GlcNAc sum was 5% more than the sum of
the decrease observed with the addition of 25 .mu.M manganese
chloride alone (10%) and 15 mM galactose alone (7%). The additive
effect was observed for the condition supplemented with 50 .mu.M
manganese chloride and 30 mM galactose. The observed 28% decrease
in the NGA2F+NGA2F-GlcNAc sum was comparable to the sum of the
decrease observed with the addition of 50 .mu.M manganese chloride
alone (18%) and 30 mM galactose alone (12%). A maximum decrease of
28% in the NGA2F+NGA2F-GlcNAc and a corresponding 25% maximum
increase in the NA1F+NA2F sum compared to the control condition was
observed with the combined addition of 50 .mu.M manganese chloride
and 30 mM galactose to chemically defined GIA-1 media.
[0055] Although specifically directed to the production of
antibodies, the following description outlines general techniques
that can be adapted for the production of other
recombinantly-expressed proteins. For example, to express a
recombinant antibody, nucleic acids encoding partial or full-length
light and heavy chains are inserted into one or more expression
vector such that the genes are operatively linked to
transcriptional and translational control sequences. (See, e.g.,
U.S. Pat. No. 6,914,128, the entire teaching of which is
incorporated herein by reference.) In this context, the term
"operatively linked" is intended to mean that an antibody gene is
ligated into a vector such that transcriptional and translational
control sequences within the vector serve their intended function
of regulating the transcription and translation of the antibody
gene. The expression vector and expression control sequences are
chosen to be compatible with the expression host cell used. The
antibody light chain gene and the antibody heavy chain gene can be
inserted into a separate vector or, more typically, both genes are
inserted into the same expression vector. The antibody genes are
inserted into an expression vector by standard methods (e.g.,
ligation of complementary restriction sites on the antibody gene
fragment and vector, or blunt end ligation if no restriction sites
are present). Prior to insertion of the antibody or
antibody-related light or heavy chain sequences, the expression
vector may already carry antibody constant region sequences. For
example, one approach to converting particular VH and VL sequences
to full-length antibody genes is to insert them into expression
vectors already encoding heavy chain constant and light chain
constant regions, respectively, such that the VH segment is
operatively linked to the CH segment(s) within the vector and the
VL segment is operatively linked to the CL segment within the
vector. Additionally or alternatively, the recombinant expression
vector can encode a signal peptide that facilitates secretion of
the antibody chain from a host cell. The antibody chain gene can be
cloned into the vector such that the signal peptide is linked
in-frame to the amino terminus of the antibody chain gene. The
signal peptide can be an immunoglobulin signal peptide or a
heterologous signal peptide (i.e., a signal peptide from a
non-immunoglobulin protein).
[0056] In addition to the antibody chain genes, a recombinant
expression vector of the invention can carry one or more regulatory
sequence that controls the expression of the antibody chain genes
in a host cell. The term "regulatory sequence" is intended to
include promoters, enhancers and other expression control elements
(e.g., polyadenylation signals) that control the transcription or
translation of the antibody chain genes. Such regulatory sequences
are described, e.g., in Goeddel; Gene Expression Technology:
Methods in Enzymology 185, Academic Press, San Diego, Calif.
(1990), the entire teaching of which is incorporated herein by
reference. It will be appreciated by those skilled in the art that
the design of the expression vector, including the selection of
regulatory sequences may depend on such factors as the choice of
the host cell to be transformed, the level of expression of protein
desired, etc. Suitable regulatory sequences for mammalian host cell
expression include viral elements that direct high levels of
protein expression in mammalian cells, such as promoters and/or
enhancers derived from cytomegalovirus (CMV) (such as the CMV
promoter/enhancer), Simian Virus 40 (SV40) (such as the SV40
promoter/enhancer), adenovirus, (e.g., the adenovirus major late
promoter (AdMLP)) and polyoma. For further description of viral
regulatory elements, and sequences thereof, see, e.g., U.S. Pat.
No. 5,168,062 by Stinski, U.S. Pat. No. 4,510,245 by Bell et al.
and U.S. Pat. No. 4,968,615 by Schaffner et al., the entire
teachings of which are incorporated herein by reference.
[0057] In addition to the antibody chain genes and regulatory
sequences, a recombinant expression vector of the invention may
carry one or more additional sequences, such as a sequence that
regulates replication of the vector in host cells (e.g., origins of
replication) and/or a selectable marker gene. The selectable marker
gene facilitates selection of host cells into which the vector has
been introduced (see e.g., U.S. Pat. Nos. 4,399,216, 4,634,665 and
5,179,017, all by Axel et al., the entire teachings of which are
incorporated herein by reference). For example, typically the
selectable marker gene confers resistance to drugs, such as G418,
hygromycin or methotrexate, on a host cell into which the vector
has been introduced. Suitable selectable marker genes include the
dihydrofolate reductase (DHFR) gene (for use in dhfr-host cells
with methotrexate selection/amplification) and the neo gene (for
G418 selection).
[0058] An antibody, or antibody portion, of the invention can be
prepared by recombinant expression of immunoglobulin light and
heavy chain genes in a host cell. To express an antibody
recombinantly, a host cell is transfected with one or more
recombinant expression vectors carrying DNA fragments encoding the
immunoglobulin light and heavy chains of the antibody such that the
light and heavy chains are expressed in the host cell and secreted
into the medium in which the host cells are cultured, from which
medium the antibodies can be recovered. Standard recombinant DNA
methodologies are used to obtain antibody heavy and light chain
genes, incorporate these genes into recombinant expression vectors
and introduce the vectors into host cells, such as those described
in Sambrook, Fritsch and Maniatis (eds), Molecular Cloning; A
Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y.,
(1989), Ausubel et al. (eds.) Current Protocols in Molecular
Biology, Greene Publishing Associates, (1989) and in U.S. Pat. Nos.
4,816,397 & 6,914,128, the entire teachings of which are
incorporated herein.
[0059] For expression of the light and heavy chains, the expression
vector(s) encoding the heavy and light chains is (are) transfected
into a host cell by standard techniques. The various forms of the
term "transfection" are intended to encompass a wide variety of
techniques commonly used for the introduction of exogenous DNA into
a prokaryotic or eukaryotic host cell, e.g., electroporation,
calcium-phosphate precipitation, DEAE-dextran transfection and the
like. Although it is theoretically possible to express the
antibodies of the invention in either prokaryotic or eukaryotic
host cells, expression of antibodies in eukaryotic cells, such as
mammalian host cells, is suitable because such eukaryotic cells,
and in particular mammalian cells, are more likely than prokaryotic
cells to assemble and secrete a properly folded and immunologically
active antibody. Prokaryotic expression of antibody genes has been
reported to be ineffective for production of high yields of active
antibody (Boss and Wood (1985) Immunology Today 6:12-13, the entire
teaching of which is incorporated herein by reference).
[0060] Suitable host cells for cloning or expressing the DNA in the
vectors herein are the prokaryote, yeast, or higher eukaryote cells
described above. Suitable prokaryotes for this purpose include
eubacteria, such as Gram-negative or Gram-positive organisms, e.g.,
Enterobacteriaceae such as Escherichia, e.g., E. coli,
Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g.,
Salmonella typhimurium, Serratia, e.g., Serratia marcescans, and
Shigella, as well as Bacilli such as B. subtilis and B.
licheniformis (e.g., B. licheniformis 41P disclosed in DD 266,710
published Apr. 12, 1989), Pseudomonas such as P. aeruginosa, and
Streptomyces. One suitable E. coli cloning host is E. coli 294
(ATCC 31,446), although other strains such as E. coli B, E. coli
X1776 (ATCC 31,537), and E. coli W3110 (ATCC 27,325) are suitable.
These examples are illustrative rather than limiting.
[0061] In addition to prokaryotes, eukaryotic microbes such as
filamentous fungi or yeast are suitable cloning or expression hosts
for polypeptide encoding vectors. Saccharomyces cerevisiae, or
common baker's yeast, is the most commonly used among lower
eukaryotic host microorganisms. However, a number of other genera,
species, and strains are commonly available and useful herein, such
as Schizosaccharomyces pombe; Kluyveromyces hosts such as, e.g., K.
lactis, K. fragilis (ATCC 12,424), K. bulgaricus (ATCC 16,045), K.
wickeramii (ATCC 24,178), K. waltii (ATCC 56,500), K. drosophilarum
(ATCC 36,906), K. thermotolerans, and K. marxianus; yarrowia (EP
402,226); Pichia pastoris (EP 183,070); Candida; Trichoderma reesia
(EP 244,234); Neurospora crassa; Schwanniomyces such as
Schwanniomyces occidentalis; and filamentous fungi such as, e.g.,
Neurospora, Penicillium, Tolypocladium, and Aspergillus hosts such
as A. nidulans and A. niger.
[0062] Suitable host cells for the expression of glycosylated
antibodies are derived from multicellular organisms. Examples of
invertebrate cells include plant and insect cells. Numerous
baculoviral strains and variants and corresponding permissive
insect host cells from hosts such as Spodoptera frugiperda
(caterpillar), Aedes aegypti (mosquito), Aedes albopictus
(mosquito), Drosophila melanogaster (fruitfly), and Bombyx mori
have been identified. A variety of viral strains for transfection
are publicly available, e.g., the L-1 variant of Autographa
californica NPV and the Bm-5 strain of Bombyx mori NPV, and such
viruses may be used as the virus herein according to the present
invention, particularly for transfection of Spodoptera frugiperda
cells. Plant cell cultures of cotton, corn, potato, soybean,
petunia, tomato, and tobacco can also be utilized as hosts.
[0063] Suitable mammalian host cells for expressing the recombinant
antibodies of the invention include Chinese Hamster Ovary (CHO
cells) (including dhfr-CHO cells, described in Urlaub and Chasin,
(1980) PNAS USA 77:4216-4220, used with a DHFR selectable marker,
e.g., as described in Kaufman and Sharp (1982) Mol. Biol.
159:601-621, the entire teachings of which are incorporated herein
by reference), NS0 myeloma cells, COS cells and SP2 cells. When
recombinant expression vectors encoding antibody genes are
introduced into mammalian host cells, the antibodies are produced
by culturing the host cells for a period of time sufficient to
allow for expression of the antibody in the host cells or secretion
of the antibody into the culture medium in which the host cells are
grown. Other examples of useful mammalian host cell lines are
monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651);
human embryonic kidney line (293 or 293 cells subcloned for growth
in suspension culture, Graham et al., J. Gen Virol. 36:59 (1977));
baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary
cells/-DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216
(1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod. 23:243-251
(1980)); monkey kidney cells (CV1 ATCC CCL 70); African green
monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical
carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC
CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human
lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB
8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells
(Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982)); MRC 5
cells; FS4 cells; and a human hepatoma line (Hep G2), the entire
teachings of which are incorporated herein by reference.
[0064] Host cells are transformed with the above-described
expression or cloning vectors for antibody production and cultured
in conventional nutrient media modified as appropriate for inducing
promoters, selecting transformants, or amplifying the genes
encoding the desired sequences.
[0065] The host cells used to produce an antibody may be cultured
in a variety of media. Commercially available media such as Ham's
F10.TM. (Sigma), Minimal Essential Medium.TM. ((MEM), (Sigma),
RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium.TM.
((DMEM), Sigma) are suitable for culturing the host cells. In
addition, any of the media described in Ham et al., Meth. Enz.
58:44 (1979), Barnes et al., Anal. Biochem. 102:255 (1980), U.S.
Pat. Nos. 4,767,704; 4,657,866; 4,927,762; 4,560,655; or 5,122,469;
WO 90/03430; WO 87/00195; or U.S. Pat. No. Re. 30,985 may be used
as culture media for the host cells, the entire teachings of which
are incorporated herein by reference. The culture conditions, such
as temperature, pH, and the like, are those previously used with
the host cell selected for expression, and will be apparent to the
ordinarily skilled artisan.
[0066] Host cells can also be used to produce portions of intact
antibodies, such as Fab fragments or scFv molecules. It is
understood that variations on the above procedure are within the
scope of the present invention. For example, in certain embodiments
it may be desirable to transfect a host cell with DNA encoding
either the light chain or the heavy chain (but not both) of an
antibody of this invention. Recombinant DNA technology may also be
used to remove some or all of the DNA encoding either or both of
the light and heavy chains that is not necessary for antigen
binding. The molecules expressed from such truncated DNA molecules
are also encompassed by the antibodies of the invention. In
addition, bifunctional antibodies may be produced in which one
heavy and one light chain are an antibody of the invention and the
other heavy and light chain are specific for an antigen other than
the original antigen by crosslinking an antibody of the invention
to a second antibody by standard chemical crosslinking methods.
[0067] In a suitable system for recombinant expression of an
antibody, or antigen-binding portion thereof, of the invention, a
recombinant expression vector encoding both the antibody heavy
chain and the antibody light chain is introduced into dhfr-CHO
cells by calcium phosphate-mediated transfection. Within the
recombinant expression vector, the antibody heavy and light chain
genes are each operatively linked to CMV enhancer/AdMLP promoter
regulatory elements to drive high levels of transcription of the
genes. The recombinant expression vector also carries a DHFR gene,
which allows for selection of CHO cells that have been transfected
with the vector using methotrexate selection/amplification. The
selected transformant host cells are cultured to allow for
expression of the antibody heavy and light chains and intact
antibody is recovered from the culture medium. Standard molecular
biology techniques are used to prepare the recombinant expression
vector, transfect the host cells, select for transformants, culture
the host cells and recover the antibody from the culture
medium.
[0068] When using recombinant techniques, the antibody can be
produced intracellularly, in the periplasmic space, or directly
secreted into the medium. In one aspect, if the antibody is
produced intracellularly, as a first step, the particulate debris,
either host cells or lysed cells (e.g., resulting from
homogenization), can be removed, e.g., by centrifugation or
ultrafiltration. Where the antibody is secreted into the medium,
supernatants from such expression systems can be first concentrated
using a commercially available protein concentration filter, e.g.,
an Amicon.TM. or Millipore Pellicon.TM. ultrafiltration unit.
[0069] Prior to the process of the invention, procedures for
purification of antibodies from cell debris initially depend on the
site of expression of the antibody. Some antibodies can be secreted
directly from the cell into the surrounding growth media; others
are made intracellularly. For the latter antibodies, the first step
of a purification process typically involves: lysis of the cell,
which can be done by a variety of methods, including mechanical
shear, osmotic shock, or enzymatic treatments. Such disruption
releases the entire contents of the cell into the homogenate, and
in addition produces subcellular fragments that are difficult to
remove due to their small size. These are generally removed by
differential centrifugation or by filtration. Where the antibody is
secreted, supernatants from such expression systems are generally
first concentrated using a commercially available protein
concentration filter, e.g., an Amicon.TM. or Millipore Pellicon.TM.
ultrafiltration unit. Where the antibody is secreted into the
medium, the recombinant host cells can also be separated from the
cell culture medium, e.g., by tangential flow filtration.
Antibodies can be further recovered from the culture medium using
the antibody purification methods of the invention.
6. EXAMPLES
6.1. Example 1
6.1.1. Materials & Methods
[0070] In the studies summarized in this example, we investigated
the effects on product quality attributes resulting from the
addition of manganese chloride and/or galactose to chemically
defined Life Technologies Gibco, GIA-1, media (proprietary
formulation) in the adalimumab-producing CHO cell line utilized in
Example 3, but adapted to GIA-1 media. The studies were performed
in either a batch process in shake flasks or a fed-batch process in
3 L bioreactors.
[0071] Growth and production media for the adalimumab-producing CHO
cell line were prepared using a proprietary Life Technologies Gibco
chemically defined media, GIA-1. Basal production and feed media
were supplemented with Manganese (II) Chloride (Sigma M1787-100 mL;
1.0 M.+-.0.1 M) and D(+)Galactose (Sigma G5388-1 kg) according to
the experimental design described in Table 1. All media were
filtered through Corning 0.5 L or 1 L filter systems 0.22 .mu.m
Poly(Ether Sulfone) (PES) and stored at 4.degree. C. until use.
[0072] The cell line utilized for both studies was generated from
the adalimumab-producing CHO cell utilized in Example 3 by adapting
it to chemically defined GIA-1 media for 7 (2 to 3 day each)
passages in a combination of 250 mL and 500 mL Corning vented
non-baffled shake flasks before freezing.
[0073] Upon thaw, for the batch shake flask study, cells were
expanded for 3 to 5 (2 to 3 day each) passages in a combination of
250 mL and 500 mL Corning vented non-baffled shake flasks.
Production cultures were initiated in duplicate 500 mL Corning
vented non-baffled shake flasks (200 mL working volume) at an
initial viable cell density (VCD) of approximately 0.5.times.106
cells/mL. Cultures were maintained on orbital shakers at 110
revolutions per minute (RPM) in a dry incubator at 35.degree. C.
and 5% CO.sub.2. The shake flask study was run in an extended batch
mode by feeding a glucose solution (1.25% (v/v) of 40% solution)
when the media glucose concentration fell below 3 g/L.
[0074] For the fed-batch bioreactor study, cells were expanded for
8 (2 to 3 day each) passages in Corning vented non-baffled shake
flasks maintained on orbital shakers at 110 RPM and in 20 L cell
bags (3 L to 10 L working volume) maintained at 20-25 RPM,
7.5.degree. angle, and 0.25 SLPM airflow in a dry incubator at
35.degree. C. and 5% CO.sub.2. Production cultures were initiated
in duplicate 3 L bioreactors (1.5 L working volume) at 35.degree.
C., 30% dissolved oxygen, 200 RPM, pH ramp from 7.1 to 6.9 over 3
days, and pH setpoint of 6.9 thereafter. A fixed split ratio of
cells to media of 1:5 was utilized to initiate the production stage
cultures. In the fed-batch mode, a chemically-defined feed from
Life Technologies Gibco, JCL-5 (proprietary formulation), was added
as follows: 3% (v/v)--day 3, 5%--day 4, 7%--day 5, 10%--day 6, and
10% --day 7. Additional glucose (1.25% (v/v) of 40% solution) was
fed when the media glucose concentration fell below 3 g/L.
[0075] For all studies with CHO cell lines described throughout
this invention, samples were collected daily and measured for cell
density and viability using a Cedex cell counter. Retention samples
for titer analysis via Poros A method were collected by
centrifugation at 12,000 RPM for 5 min when the culture viability
began declining. The cultures were harvested by collecting 125 mL
aliquots and centrifuging at 3,000 RPM for 30 min when culture
viability was near or below 50%. All supernatants were stored at
-80.degree. C. until analysis.
[0076] For all studies, the harvest samples were Protein A purified
and prepared for the oligosaccharide assay using the following
procedures. As a first step in the process of establishing the
identity and quantifying the oligosaccharides, they are released
from the protein by enzymatic digestion with N-glycanase. Once the
glycans are released, the free reducing end of each glycan is
labeled by reductive amination with a fluorescent tag,
2-aminobenzamide (2-AB). The resulting labeled glycans are
separated by normal-phase HPLC (NP-HPLC) in acetonitrile: 50 mM
ammonium formate, pH 4.4, and detected by a fluorescence detector.
Quantitation is based on the relative area percent of detected
sugars. Throughout this invention, the relative area percentages of
the agalactosyl fucosylated biantennary oligosaccharides, denoted
as NGA2F+NGA2F-GlcNAc sum, and the galactose-containing fucosylated
biantennary oligosaccharides NA1F+NA2F sum are reported and
discussed.
6.1.2. Experimental Design
[0077] As detailed in Table 1, for the batch shake flask study,
manganese chloride was supplemented at the following concentrations
in production media: 0, 40, 60, 80, and 100 .mu.M. Galactose was
supplemented at the following levels in production media: 0, 10,
20, 40, and 100 mM. Individual and combined additions of manganese
chloride and galactose were studied using a comprehensive design
divided into 3 sets of experiments. Each experiment had a control
culture for direct comparison of culture growth, productivity, and
product quality. Production media used for the control cultures was
not supplemented with manganese chloride or galactose. Culture
growth, productivity, and product quality data for control cultures
is the average of the 3 experiments.
[0078] For the fed-batch bioreactor study, manganese chloride and
galactose were supplemented to both production and feed media in
the following combinations: 40 .mu.M manganese chloride and 20 mM
galactose; 40 .mu.M manganese chloride and 40 mM galactose (Table
2). Basal and feed media for the control cultures were not
supplemented with manganese chloride or galactose.
TABLE-US-00001 TABLE 1 Experimental design for the batch shake
flasks study (Example 1) Manganese Galactose (.mu.M) (mM) ID 0 0
Mn(0) Gal(0) 0 10 Mn(0) Gal(10) 0 20 Mn(0) Gal(20) 0 40 Mn(0)
Gal(40) 0 100 Mn(0) Gal(100) 40 0 Mn(40) Gal(0) 80 0 Mn(80) Gal(0)
100 0 Mn(100) Gal(0) 40 10 Mn(40) Gal(10) 40 20 Mn(40) Gal(20) 40
40 Mn(40) Gal(40) 40 100 Mn(40) Gal(100) 60 20 Mn(60) Gal(20) 60 40
Mn(60) Gal(40) 60 100 Mn(60) Gal(100) 80 20 Mn(80) Gal(20) 80 40
Mn(80) Gal(40) 80 100 Mn(80) Gal(100) 100 20 Mn(100) Gal(20) 100 40
Mn(100) Gal(40) 100 100 Mn(100) Gal(100)
TABLE-US-00002 TABLE 1 Experimental design for the fed- batch 3 L
bioreactors study (Example 1) Manganese Galactose (.mu.M) (mM) ID 0
0 Mn(0) Gal(0) 40 20 Mn(40) Gal(20) 40 40 Mn(40) Gal(40)
6.1.3. Culture Growth & Productivity
[0079] For the shake flasks experiments, cell growth and viability
profiles of cultures in production media supplemented with
galactose in the 0 to 100 mM concentration range and/or manganese
chloride up to 80 .mu.M concentration were comparable to control
cultures without manganese and/or galactose added (FIGS. 1A, 1B).
Cultures grown in media supplemented with manganese chloride at 100
.mu.M concentration and galactose concentrations in the 0 to 100 mM
range experienced growth lag and decreased viability for the first
4 production days, likely due to toxic effects of manganese at this
concentration. However, toxicity effects were overcome after
production day 4. Harvest titer for most experimental conditions
was 3% to 14% higher than the average harvest titer for the control
cultures (FIG. 1C). All three control cultures had comparable
growth profiles and productivity. For the bioreactors fed-batch
experiment, culture growth, viability profiles, and harvest titer
were comparable for all conditions (FIGS. 2A, 2B, 2C).
6.1.4. Oligosaccharide Analysis
[0080] In this example, the modulation of galactosylation with the
addition of manganese chloride and/or galactose to chemically
defined media GIA-1 was explored using the adalimumab-producing CHO
cell line utilized in Example 3, but adapted to GIA-1 media.
6.1.4.1. Batch Shake Flask Study
[0081] For the shake flask study, the addition of manganese
chloride alone within the range of 0 to 100 .mu.M to production CDM
GIA-1 decreased the NGA2F+NGA2F-GlcNac sum in a concentration
dependent manner and increased the NA1F+NA2F sum by approximately
the same percentage. A maximum change of 9% in the
NGA2F+NGA2F-GlcNac and 8% in the NA1F+NA2F oligosaccharides was
observed with the addition of 100 .mu.M manganese chloride (FIG.
3). Manganese doses greater than 100 .mu.M were not explored
further due to cytotoxicity effects. Similarly, a concentration
dependent decrease in the NGA2F+NGA2F-GlcNac sum and a
corresponding increase in the NA1F+NA2F sum were observed with the
addition of galactose alone in the range of 0 to 100 mM to
production CDM GIA-1. A maximum change of 7% in the
NGA2F+NGA2F-GlcNac and the NA1F+NA2F oligosaccharides was observed
with the addition of 100 mM galactose.
[0082] The effect on modulation of galactosylation of adalimumab in
CDM GIA-1 with the combined addition of manganese chloride and
galactose was synergistic. Combined addition of manganese chloride
and galactose decreased the NGA2F+NGA2F-GlcNac sum and increased
the NA1F+NA2F sum by a larger percentage than by adding manganese
or galactose alone and summing up their individual effects (FIGS. 4
and 5). For example, addition of 40 .mu.M manganese chloride alone
reduced the NGA2F+NGA2F-GlcNac sum by 6%, and addition of 40 mM
galactose alone decreased the NGA2F+NGA2F-GlcNac sum by 6%.
However, the combined addition of manganese chloride and galactose
at these same concentrations (i.e. 40 .mu.M manganese+40 mM
galactose) led to an 18% reduction in the NGA2F+NGA2F-GlcNac sum,
6% higher than their combined individual contributions to the
reduction of the NGA2F+NGA2F-GlcNac sum. We define this effect as
being synergistic and maintain this definition throughout the
invention. A maximum decrease compared to the control condition of
26% in the NGA2F+NGA2F-GlcNac sum was observed with the combined
addition of 100 .mu.M manganese chloride and 100 mM galactose.
6.1.4.2. Fed-Batch Bioreactor Study
[0083] For the fed-batch 3 L bioreactors study, two manganese
chloride and galactose combinations were studied and we show that
the decrease in the NGA2F+NGA2F-GlcNac and the corresponding
increase in the NA1F+NA2F oligosaccharides was scale (1.5 L vs. 200
mL) and process independent (fed-batch in controlled bioreactor
environment vs. batch in shake flasks). Combined addition of 40
.mu.M manganese chloride and 20 mM galactose to both production
basal CDM GIA-1 and feed CDM JCL-5 decreased the NGA2F+NGA2F-GlcNac
sum by 26% and increased the NA2F+NA2F sum by 27% compared to the
control cultures (FIG. 6). A further increase in the galactose
concentration to 40 mM in addition to manganese supplementation at
40 .mu.M concentration resulted in an additional 3% decrease in the
NGA2F+NGA2F-GlcNac sum, and a corresponding 3% increase in the
NA1F+NA2F sum.
6.2. Example 2
6.2.1. Materials & Methods
[0084] In the study summarized in this example, we investigated the
effects on product quality attributes resulting from the addition
of manganese chloride and/or galactose to the chemically defined
media Thermo Scientific HyClone CDM4CHO using the
adalimumab-producing CHO cell line used in Example 1 further
adapted to HyClone media.
[0085] Growth and production media for the adalimumab-producing CHO
cell line were prepared using Thermo Scientific HyClone chemically
defined media CDM4CHO without L-glutamine (Catalogue # SH30558.02).
Production media was supplemented with Manganese (II) Chloride
(Sigma M1787-100 mL; 1.0 M.+-.0.1 M) and D(+)Galactose (Sigma
G5388-1 kg) according to the experimental design described in Table
3. All media were filtered through Corning 0.5 L or 1 L (0.22 .mu.m
PES) filter systems and stored at 4.degree. C. until use.
[0086] Upon thaw, cells were adapted to and expanded in HyClone
CDM4CHO media for 5 (2 to 3 day each) passages in a combination of
250 mL, 500 mL, and 1000 mL Corning vented non-baffled shake
flasks. Production cultures were initiated in duplicate 500 mL
Corning vented non-baffled shake flasks (200 mL working volume) at
an initial VCD of approximately 0.5.times.106 cells/mL. Cultures
were maintained on orbital shakers at 110 RPM in a dry incubator at
35.degree. C. and 5% CO.sub.2. A glucose solution (1.25% (v/v) of
40% solution) was fed when the media glucose concentration fell
below 3 g/L.
6.2.2. Experimental Design
[0087] As detailed in Table 3, manganese chloride was supplemented
at the following concentrations in production media: 0, 10, 20, and
40 .mu.M. Galactose was supplemented at the following levels in
production media: 0, 10, 20, and 100 mM. Production media for the
control cultures was not supplemented with manganese chloride or
galactose.
TABLE-US-00003 TABLE 3 Experimental design for Example 2 Manganese
Galactose (.mu.M) (mM) ID 0 0 Mn(0) Gal(0) 0 10 Mn(0) Gal(10) 0 20
Mn(0) Gal(20) 0 40 Mn(0) Gal(40) 10 0 Mn(10) Gal(0) 20 0 Mn(20)
Gal(0) 40 0 Mn(40) Gal(0) 10 10 Mn(10) Gal(10) 20 20 Mn(20) Gal(20)
40 40 Mn(40) Gal(40)
6.2.3. Culture Growth & Productivity
[0088] Cell growth and viability profiles of cultures in production
HyClone CDM4CHO supplemented with galactose in the 0 to 40 mM
concentration range and/or manganese chloride up to 10 .mu.M
concentration were comparable to the control cultures without
manganese and/or galactose added (FIGS. 7A, 7B). Increasing the
concentration of manganese chloride in HyClone CDM4CHO production
media to 20 .mu.M or 40 .mu.M slowed down culture growth. Manganese
doses greater than 40 .mu.M were not explored further due to the
observed growth inhibition effects. Harvest titer for all
conditions was comparable to the control (data not shown).
6.2.4. Oligosaccharide Analysis
[0089] In this example, the modulation of galactosylation with the
addition of manganese chloride and/or galactose to the commercially
available HyClone CDM4CHO was explored using the
adalimumab-producing CHO cell line used Example 1 further adapted
to HyClone media.
[0090] The addition of manganese chloride alone within the range of
0 to 40 .mu.M to production CDM HyClone CDM4CHO decreased the
NGA2F+NGA2F-GlcNac sum by a maximum of 5% in a concentration
dependent manner (FIG. 8). A comparable maximum increase of 4% in
the NA1F+NA2F sum was achieved. Addition of galactose alone up to a
maximum concentration of 40 mM yielded a 6% maximum decrease in the
NGA2F+NGA2F-GlcNac sum and a corresponding 6% increase in the
NA1F+NA2F sum.
[0091] An additive effect was observed in cultures supplemented
with both manganese chloride and galactose. The combined addition
of manganese chloride and galactose decreased the
NGA2F+NGA2F-GlcNac sum and increased the NA1F+NA2F sum by a
comparable percentage as when manganese or galactose were added
alone and their individual effects were summed up (FIG. 9). For
example, addition of 40 .mu.M manganese chloride alone reduced the
NGA2F+NGA2F-GlcNac sum by 5%, and addition of 40 mM galactose alone
decreased the NGA2F+NGA2F-GlcNac sum by 6%. The combined addition
of manganese chloride and galactose at these same concentrations
(i.e. 40 .mu.M manganese+40 mM galactose) led to a 12% reduction in
the NGA2F+NGA2F-GlcNac sum. We define this effect as being additive
and maintain this definition throughout the invention.
[0092] The highest percentage decrease in the NGA2F+NGA2F-GlcNac
sum of 12% and the corresponding 11% increase in the NA1F+NA2F sum
was observed for the culture supplemented with 40 .mu.M manganese
chloride and 40 mM galactose.
6.3. Example 3
6.3.1. Materials & Methods
[0093] In the study summarized in this example, we investigated the
effects on product quality attributes resulting from the addition
of manganese chloride and/or galactose to a hydrolysate-based media
(proprietary formulation) in an adalimumab-producing CHO cell
line.
[0094] Growth and production media for the adalimumab-producing CHO
cell line were prepared using yeast and soy hydrolysates according
to a proprietary formulation. Production media was supplemented
with Manganese (II) Chloride (Sigma M1787-100 mL; 1.0 M.+-.0.1 M)
and D(+)Galactose (Sigma G5388-1 kg) according to the experimental
design described in Table 4. All media were filtered through
Corning 0.5 L or 1 L filter systems (0.22 .mu.m PES) and stored at
4.degree. C. until use.
[0095] Upon thaw, cells were expanded for 9 (2 to 3 day each)
passages in a combination of 250 mL, 500 mL, and 1000 mL Corning
vented non-baffled shake flasks. Production cultures were initiated
in duplicate 500 mL Corning vented non-baffled shake flasks (200 mL
working volume) at an initial VCD of approximately 0.5.times.106
cells/mL. Cultures were maintained on orbital shakers at 110 RPM in
a dry incubator at 35.degree. C. and 5% CO.sub.2. A glucose
solution (1.25% (v/v) of 40% solution) was fed when the media
glucose concentration fell below 3 g/L.
6.3.2. Experimental Design
[0096] As detailed in Table 4, manganese chloride was supplemented
at the following concentrations in production media: 0, 10, 20, and
40 .mu.M. Galactose was supplemented at the following levels in
production media: 0, 10, 20, and 40 mM. Production media for the
control cultures was not supplemented with manganese chloride or
galactose.
TABLE-US-00004 TABLE 4 Experimental design for Example 3 Manganese
Galactose (.mu.M) (mM) ID 0 0 Mn(0) Gal(0) 0 10 Mn(0) Gal(10) 0 20
Mn(0) Gal(20) 0 40 Mn(0) Gal(40) 10 0 Mn(10) Gal(0) 20 0 Mn(20)
Gal(0) 40 0 Mn(40) Gal(0) 10 10 Mn(10) Gal(10) 20 20 Mn(20) Gal(20)
40 40 Mn(40) Gal(40)
6.3.3. Culture Growth & Productivity
[0097] Cell growth of most cultures in the hydrolysate-based media
supplemented with galactose in the 0 to 40 mM concentration range
and/or manganese chloride in the 0 to 40 .mu.M concentration was
slower compared to the control cultures without manganese or
galactose added (FIG. 10A). However, all cultures reached a
comparable peak viable cell density. Some cultures supplemented
with 20 .mu.M or 40 .mu.M manganese chloride showed decreased
viability by day 3 of production culture, but recovered as the
cultures progressed (FIG. 10B). The culture supplemented with 10
.mu.M manganese chloride was studied with a second control
condition (B) in a separate experiment. Both these cultures grew to
slightly higher maximum VCD compared to all other cultures, however
results were within historical variation. Harvest titer for all
conditions was comparable to the control (data not shown).
6.3.4. Oligosaccharide Analysis
[0098] In this example, the modulation of galactosylation by the
addition of manganese chloride and/or galactose to a
hydrolysate-based media was explored using an adalimumab-producing
CHO cell line in shake flasks.
[0099] The addition of manganese chloride alone within the range of
0 to 40 .mu.M to hydrolysate-based production media decreased the
NGA2F+NGA2F-GlcNac sum by approximately 1%, a change that is within
the oligosaccharide assay variability (FIG. 11). The addition of
galactose alone up to a maximum concentration of 40 mM yielded a
maximum decrease of 4% in the NGA2F+NGA2F-GlcNac sum and a
corresponding 4% maximum increase in the NA1F+NA2F sum.
[0100] The oligosaccharide profile changes achieved with the
addition of galactose alone are comparable to the changes recorded
when combinations of galactose and manganese chloride were added to
the hydrolysate-based media. The combined addition of manganese
chloride ranging from 0 to 40 .mu.M and galactose ranging from 0 to
40 mM to hydrolysate-based media led to an approximate 5% maximum
decrease in the NGA2F+NGA2F-GlcNac sum and a corresponding 3%
increase in the NA1F+NA2F sum (FIG. 12). The highest percentage
decrease of 5% in the NGA2F+NGA2F-GlcNac sum and the corresponding
4% increase in the NA1F+NA2F sum was observed for the culture
supplemented with 40 mM galactose and either 20 .mu.M or 40 .mu.M
manganese chloride.
6.4. Example 4
6.4.1. Materials & Methods
[0101] In the study summarized in this example, we investigated the
effects on product quality attributes resulting from the addition
of manganese chloride and/or galactose to chemically defined Life
Technologies Gibco GIA-1 media using a different adalimumab
producing CHO cell line than in Examples 1, 2, and 3, named CHO
cell line #2.
[0102] Growth and production media for the adalimumab-producing CHO
cell line #2 were prepared using a proprietary Life Technologies
Gibco chemically defined media, GIA-1. Production media only was
supplemented with with Manganese (II) Chloride (Sigma M1787-100 mL;
1.0 M.+-.0.1 M) and D(+)Galactose (Sigma G5388-1 kg) according to
the experimental design described in Table 5. All media were
filtered through Corning 0.5 L or 1 L filter systems (0.22 .mu.m
PES) and stored at 4.degree. C. until use.
[0103] Upon thaw, cells were expanded for 5 to 8 (2 to 3 day each)
passages in a combination of 250 mL, 500 mL, and 1000 mL Corning
vented non-baffled shake flasks. Production cultures were initiated
in duplicate 500 mL Corning vented non-baffled shake flasks (200 mL
working volume) at an initial VCD of approximately 0.5.times.106
cells/mL. Cultures were maintained on orbital shakers at 180 RPM in
a dry incubator at 35.degree. C. and 5% CO.sub.2. A glucose
solution (1.25% (v/v) of 40% solution) was fed when the media
glucose concentration fell below 3 g/L.
6.4.2. Experimental Design
[0104] As detailed in Table 5, manganese chloride was supplemented
at the following concentrations in production media: 0, 10, 20, and
40 .mu.M. Galactose was supplemented at the following levels in
production media: 0, 10, and 20 mM. Production media for the
control cultures was not supplemented with manganese chloride or
galactose. This study was run in 2 blocks.
TABLE-US-00005 TABLE 5 Experimental design for Example 4 Manganese
Galactose (.mu.M) (mM) ID Block I 0 0 Mn(0) Gal(0) 20 0 Mn(20)
Gal(0) 10 10 Mn(10) Gal(10) 20 20 Mn(20) Gal(20) 40 20 Mn(40)
Gal(20) Block II 0 0 Mn(0) Gal(0) 0 10 Mn(0) Gal(10) 0 20 Mn(0)
Gal(20) 10 0 Mn(10) Gal(0)
6.4.3. Culture Growth & Productivity
[0105] Culture growth, viability profiles, and harvest titer of
cultures in production CDM GIA-1 supplemented with galactose in the
0 to 20 mM concentration range and/or manganese chloride in the 0
to 40 .mu.M concentration range were comparable to the control
cultures without manganese or galactose added (FIGS. 13A, 13B;
harvest titer data not shown).
6.4.4. Oligosaccharide Analysis
[0106] In this example, the modulation of galactosylation by the
addition of manganese chloride and/or galactose to chemically
defined GIA-1 media was explored using the adalimumab-producing CHO
cell line #2.
[0107] The addition of manganese chloride alone within the range of
0 to 20 .mu.M to production CDM GIA-1 decreased the
NGA2F+NGA2F-GlcNac sum in a concentration dependent manner and
increased the NA1F+NA2F sum by approximately the same percentage. A
maximum decrease of 22% in the NGA2F+NGA2F-GlcNac sum and a maximum
corresponding increase of 23% in the NA1F+NA2F sum was observed
with the addition of 20 .mu.M manganese chloride (FIG. 14).
Similarly, a concentration dependent decrease in the
NGA2F+NGA2F-GlcNac sum and a corresponding increase in the
NA1F+NA2F sum was observed with the addition of galactose alone in
the range of 0 to 20 mM. A maximum decrease of 9% in the
NGA2F+NGA2F-GlcNac sum and a corresponding maximum increase of 10%
in the NA1F+NA2F sum was observed with the addition of 20 mM
galactose.
[0108] An additive effect was observed for the oligosaccharide
profiles of adalimumab produced in cultures supplemented with the
combined addition of manganese chloride and galactose to GIA-1
media (FIG. 15). For example, addition of 10 .mu.M manganese
chloride alone reduced the NGA2F+NGA2F-GlcNac sum by 18%, and
addition of 10 mM galactose alone decreased the NGA2F+NGA2F-GlcNac
sum by 6%. The combined addition of manganese chloride and
galactose at these same concentrations led to a 24% reduction in
the NGA2F+NGA2F-GlcNac sum. The highest percentage decrease of 35%
in the NGA2F+NGA2F-GlcNac sum and the corresponding increase of 37%
in the NA1F+NA2F sum were observed for the culture supplemented
with 40 .mu.M manganese chloride and 20 mM galactose.
6.5. Example 5
6.5.1. Materials & Methods
[0109] In the study summarized in this example, we investigated the
effects on product quality attributes resulting from the addition
of manganese chloride and/or galactose to chemically defined Life
Technologies Gibco GIA-1 media using a different
adalimumab-producing CHO cell line than in Examples 1, 2, 3, and 4,
named CHO cell line #3.
[0110] Growth and production media for the adalimumab-producing CHO
cell line #3 were prepared using the proprietary Life Technologies
Gibco chemically defined media, GIA-1. Basal production and feed
media were supplemented with Manganese (II) Chloride (Sigma
M3634-100 g) and D(+)Galactose (Sigma G5388-1 kg) according to the
experimental design described in Table 6.
[0111] Upon thaw, cells were expanded in Corning vented non-baffled
shake flasks maintained on orbital shakers at 140 RPM, and in 10 L
cell bags (2 L working volume) maintained at 25 RPM, 7.degree.
angle, and 0.25 SLPM airflow in a dry incubator at 36.degree. C.
and 5% CO.sub.2. Production cultures were initiated in 3 L
bioreactors (1.4 L initial working volume) at 36.degree. C., 30%
dissolved oxygen, 200 RPM, and pH 6.9.+-.0.2. A fixed split ratio
of cells to media of 1:6.7 was utilized to initiate the production
stage cultures. A temperature shift was performed when the culture
VCD reached a value higher than 5.times.106 cells/mL. The
chemically-defined feed from Life Technologies Gibco JCL-5 was
added as follows: 4% (v/v)--day 2, 6%--day 4, 8%--day 6, 10%--day
8, and 10%--day 10. Additional 400 g/L glucose was added to the
reactor cultures as needed to ensure glucose levels did not
deplete. Bioreactors were harvested at a viability of approximately
50% or on production day 17, whichever condition occurred
first.
6.5.2. Experimental Design
[0112] As detailed in Table 6, manganese chloride was supplemented
at the following concentrations in both production and feed media:
0, 0.1, 0.2, 0.5, and 1.0 .mu.M. Galactose was supplemented at 0
and 30 mM concentrations in both production and feed media. In
addition, a combined manganese chloride and galactose
supplementation strategy was utilized for the production basal and
feed media at either 0.2 or 0.5 .mu.M manganese chloride plus 30 mM
galactose. Basal and feed media for the control cultures were not
supplemented with manganese chloride or galactose.
TABLE-US-00006 TABLE 6 Experimental design for Example 5 Manganese
Galactose (.mu.M) (mM) ID 0 0 Mn(0) Gal(0) 0.1 0 Mn(0.1) Gal(0) 0.2
0 Mn(0.2) Gal(0) 0.5 0 Mn(0.5) Gal(0) 1.0 0 Mn(1.0) Gal(0) 0 30
Mn(0) Gal(30) 0.2 30 Mn(0.2) Gal(30) 0.5 30 Mn(0.5) Gal(30)
6.5.3. Culture Growth & Productivity
[0113] Growth profiles of most cultures supplemented with manganese
chloride and/or galactose were comparable to the control culture
except for the cultures supplemented with 30 mM galactose alone or
in combination with 0.2 .mu.M manganese chloride which grew slower
and reached a lower peak VCD (FIG. 16A). However, the culture
supplemented with 0.5 .mu.M manganese chloride and 30 mM galactose
had a growth profile comparable to the control culture indicating
that neither manganese chloride nor galactose at the concentrations
studied are detrimental to culture growth. Viability profiles and
harvest titer were comparable to the control condition (FIGS. 16B,
16C).
6.5.4. Oligosaccharide Analysis
[0114] In this example, the modulation of galactosylation with the
addition of manganese chloride and/or galactose to chemically
defined media GIA-1 was explored using the adalimumab-producing CHO
cell line #3.
[0115] The addition of manganese chloride alone within the range of
0 to 1 .mu.M to production CDM GIA-1 decreased the
NGA2F+NGA2F-GlcNac sum in a concentration dependent manner and
increased the NA1F+NA2F sum by approximately the same percentage. A
maximum decrease of 26% in the NGA2F+NGA2F-GlcNAc and a
corresponding increase of 28% in the NA1F+NA2F oligosaccharides
were observed with the addition of 1 .mu.M manganese chloride (FIG.
17). The addition of galactose alone at 30 mM concentration to
production CDM GIA-1 decreased the NGA2F+NGA2F-GlcNAc sum by 4% and
increased the NA1F+NA2F sum by 3%.
[0116] When manganese chloride and galactose were supplemented
together into the production basal and feed media, the results
demonstrated a synergistic benefit towards the decrease in the
NGA2F+NGA2F-GlcNAc and the increase in the NA1F+NA2F
oligosaccharides which is consistent with the results demonstrated
in Example 1 (FIG. 18). For example, at 0.2 .mu.M manganese
chloride plus 30 mM galactose the observed 25% decrease in the
NGA2F+NGA2F-GlcNAc sum was 6% more than the sum of the decrease
observed with the addition of 0.2 .mu.M manganese chloride alone
(15%) and that of 30 mM galactose alone (4%). Similarly the
resulting 24% increase in the NA1F+NA2F sum was more than the sum
of the increase observed with the addition of 0.2 .mu.M manganese
chloride alone (16%) and that of 30 mM galactose alone (3%). The
combined supplementation of 0.5 .mu.M manganese chloride+30 mM
galactose also demonstrated a synergistic effect on the
galactosylation profile of adalimumab produced in the CHO cell line
#3. A maximum decrease compared to the control condition of 34% in
the NGA2F+NGA2F-GlcNac and a corresponding 34% maximum increase in
the NA1F+NA2F oligosaccharides was observed with the combined
addition of 0.5 .mu.M manganese chloride and 30 mM galactose to
chemically defined GIA-1 media.
6.6. Example 6
6.6.1. Materials & Methods
[0117] In the study summarized in this example, we investigated the
effects on product quality attributes resulting from the addition
of manganese chloride and/or galactose to chemically defined Life
Technologies Gibco PFBM-3 basal medium and PFFM-4 feed medium
(proprietary formulation) using an adalimumab-producing NSO cell
line in a fed-batch process in shake flasks.
[0118] Growth and production media for the adalimumab-producing NSO
cell line were prepared using a proprietary Life Technologies Gibco
chemically defined media, PFBM-3 basal medium plus PFFM-4 feed
medium. Production and feed media were supplemented with Manganese
(II) Chloride (Sigma M1787-100 mL; 1.0 M.+-.0.1 M) and
D(+)Galactose (Sigma G5388-1 kg) according to the experimental
design described in Table 7.
[0119] Upon thaw, cells were expanded for 3 to 5 (2 days each)
passages in a combination of 250 mL, 500 mL, 1 L, 2 L and 3 L
Corning vented non-baffled shake flasks. Production cultures were
initiated in single 1 L Corning vented non-baffled shake flasks
(240 mL initial working volume) at an initial VCD of approximately
2.5.times.105 cells/mL. Cultures were maintained on orbital shakers
at 100 RPM in a dry incubator at 37.degree. C. and 5% CO.sub.2. The
shake flask study was run in a fed-batch mode and the culture was
fed PFFM-4 as follows: 24 mL--day 2, 28.8 mL--day 4, 28.8 mL--day
6, and 28.8 mL--day 8.
[0120] Samples were collected every 2 days and measured for cell
density and viability using a Cedex cell counter. Retention samples
for titer analysis via Poros A method were collected daily
beginning on Day 8 by centrifugation at 2,000 g for 10 min and then
filtered through 0.2 um PVDF syringe filter. The cultures were
harvested on production day 10. The entire culture was collected,
chilled on ice to approximately 0.degree. C. for 1.5 hours, the
cells and debris flocculated at pH 5.0 by the addition of 1M citric
acid and held for 15 minutes, and centrifuged at 4000.times.g for
15 min at 5.degree. C. The supernatant was passed through 0.20 um
Millipore Stericup PES filters, and, immediately post filtration,
the acidified clarified cell-free harvest was neutralized with 2M
Tris to pH 7.1.+-.0.2. The cell free harvest was transferred to
PETG bottles and stored at -80.degree. C. until analysis.
6.6.2. Experimental Design
[0121] As detailed in Table 7, manganese chloride was supplemented
at the following concentrations in both production and feed media:
0, 0.2, and 0.5 .mu.M. Galactose was supplemented at the following
levels in both production and feed media: 0, 1, 4, 5, and 10 mM.
Manganese chloride and galactose were added in a full factorial,
two level DOE design for the 0, 1, and 4 mM galactose conditions
and all concentrations of manganese chloride. Individual and
combined additions of manganese chloride and galactose were studied
using a comprehensive design divided into 2 sets of experiments.
Each experiment had a control culture for direct comparison of
culture growth, productivity, and product quality. Production
medium for control cultures was not supplemented with manganese
chloride or galactose.
TABLE-US-00007 TABLE 7 Experimental design for Example 6 Manganese
Galactose (.mu.M) (mM) ID Block I 0 0 Mn(0) Gal(0) 0 5 Mn(0) Gal(5)
0 10 Mn(0) Gal(10) Block II 0 0 Mn(0) Gal(0) 0.2 0 Mn(0.2) Gal(0)
0.5 0 Mn(0.5) Gal(0) 0 1 Mn(0) Gal(1) 0.2 1 Mn(0.2) Gal(1) 0.5 1
Mn(0.5) Gal(1) 0 4 Mn(0) Gal(4) 0.2 4 Mn(0.2) Gal(4) 0.5 4 Mn(0.5)
Gal(4)
6.6.3. Culture Growth & Productivity
[0122] Culture growth and viability profiles in production media
supplemented with galactose in the 0 to 5 mM concentration range
and/or manganese chloride up to 0.5 .mu.M concentration were
comparable to the control condition without manganese or galactose
added (FIGS. 19A, 19B). The addition of galactose at 10 mM
concentration had a detrimental effect on culture growth and
productivity. The cultures in the Block I experiment had a lower
maximum VCD and overall lower viability than the cultures in the
Block II experiment. All cultures in the Block II experiment showed
similar VCD and viability profiles. Harvest titer for most
experimental conditions was comparable to the harvest titer for the
control condition except for the titer of the culture supplemented
with 10 mM galactose, which was 60% lower (FIG. 19C).
6.6.4. Oligosaccharide Analysis
[0123] In this example, the modulation of galactosylation by the
addition of manganese chloride and/or galactose to chemically
defined PFBM-3/PFFM-4 media was explored using an
adalimumab-producing NSO cell line in a fed-batch process in shake
flasks.
[0124] The addition of manganese chloride alone within the range of
0 to 0.5 .mu.M to CDM PFBM-3/PFFM-4 decreased the
NGA2F+NGA2F-GlcNac sum in a concentration dependent manner and
increased the NA1F+NA2F sum by approximately the same percentage. A
maximum decrease of 18% in the NGA2F+NGA2F-GlcNac sum and a
corresponding increase of 20% in the NA1F+NA2F sum were observed
with the addition of 0.5 .mu.M manganese chloride (FIG. 20).
Manganese doses greater than 0.5 .mu.M were not explored further
due to cytotoxicity effects. Similarly, a concentration dependent
decrease in the NGA2F+NGA2F-GlcNac sum and a corresponding increase
in the NA1F+NA2F sum were observed with the addition of galactose
alone in the range of 0 to 10 mM to CDM PFBM-3/PFFM-4. A maximum
decrease of 14% in the NGA2F+NGA2F-GlcNac sum and a corresponding
increase of 15% in the NA1F+NA2F sum was observed with the addition
of 10 mM galactose.
[0125] The effect on modulation of galactosylation of adalimumab
produced in a NSO cell line in CDM PFBM-3/PFFM-4 supplemented with
manganese chloride and galactose was synergistic (FIG. 21). For
example, addition of 0.2 .mu.M manganese chloride alone reduced the
NGA2F+NGA2F-GlcNac sum by 12%, and addition of 4 mM galactose alone
decreased the NGA2F+NGA2F-GlcNac sum by 2%. However, the combined
addition of manganese chloride and galactose at these same
concentrations (i.e. 0.2 .mu.M manganese+4 mM galactose) led to a
19% reduction in the NGA2F+NGA2F-GlcNac sum, 5% higher than their
combined individual contributions. A maximum decrease of .about.26%
in the NGA2F+NGA2F-GlcNac sum and a corresponding 28% increase in
the NA1F+NA2F sum were observed with the combined addition of 0.5
.mu.M manganese chloride and 4 mM galactose.
6.7. Example 7
6.7.1. Materials & Methods
[0126] In the study summarized in this example, we investigated the
effects on product quality attributes resulting from the addition
of manganese chloride and/or galactose to chemically defined Life
Technologies Gibco GIA-1 media in a CHO cell line producing a
monoclonal antibody generically named mAb #1.
[0127] Growth and production media for the CHO cell line producing
mAb #1 were prepared using a proprietary Life Technologies Gibco
chemically defined media, GIA-1. Production media only was
supplemented with Manganese (II) Chloride (Sigma M1787-100 mL; 1.0
M.+-.0.1 M) and D(+)Galactose (Sigma G5388-1 kg) according to the
experimental design described in Table 8. All media were filtered
through Corning 0.5 L or 1 L filter systems (0.22 .mu.m PES) and
stored at 4.degree. C. until use.
[0128] Upon thaw, cells were expanded for 6 (3 day each) passages
in a combination of 250 mL, 500 mL, and 1000 mL Corning vented
non-baffled shake flasks. Production cultures were initiated in
duplicate 500 mL Corning vented non-baffled shake flasks (200 mL
working volume) at an initial VCD of approximately 0.5.times.106
cells/mL. Cultures were maintained on orbital shakers at 125 RPM in
a dry incubator at 35.degree. C. and 5% CO.sub.2. A glucose
solution (1.25% (v/v) of 40% solution) was fed when the media
glucose concentration fell below 3 g/L.
6.7.2. Experimental Design
[0129] As detailed in Table 8, manganese chloride was supplemented
at the following levels in production media: 0, 10, 20, and 40
.mu.M. Galactose was supplemented at the following levels in
production media: 0, 10, 20, and 100 mM. Production media for the
control cultures was not supplemented with manganese chloride or
galactose.
TABLE-US-00008 TABLE 8 Experimental design for Example 7 Manganese
Galactose (.mu.M) (mM) ID 0 0 Mn(0) Gal(0) 0 10 Mn(0) Gal(10) 0 20
Mn(0) Gal(20) 0 40 Mn(0) Gal(40) 10 0 Mn(10) Gal(0) 20 0 Mn(20)
Gal(0) 40 0 Mn(40) Gal(0) 10 10 Mn(10) Gal(10) 20 20 Mn(20) Gal(20)
40 40 Mn(40) Gal(40)
6.7.3. Culture Growth & Productivity
[0130] Cultures supplemented with manganese chloride alone in the
concentration range of 0 to 20 .mu.M grew comparable to the control
cultures (FIG. 22A). Cultures supplemented with galactose alone or
with the combination of 20 .mu.M manganese and 20 mM galactose grew
to a lower maximum VCD compared to the control, but had the same
growth rate until the peak VCD was achieved on production day 6.
These cultures ended a day earlier, on production day 9 (FIG. 22B).
Cultures supplemented with 40 .mu.M manganese chloride and
galactose at all levels studied along with the culture supplemented
with 10 .mu.M manganese chloride and 10 mM galactose experienced
slower growth and decreased peak VCD compared to the control.
Harvest titer was 3-24% lower than the control condition (data not
shown).
6.7.4. Oligosaccharide Analysis
[0131] In this example, the modulation of galactosylation by the
addition of manganese chloride and/or galactose to chemically
defined Life Technologies Gibco GIA-1 media was explored using a
CHO cell line producing the monoclonal antibody mAb #1.
[0132] The addition of manganese chloride alone within the range of
0 to 40 .mu.M to production CDM GIA-1 decreased the
NGA2F+NGA2F-GlcNac sum by a maximum of 26% (FIG. 23). A comparable
maximum increase of 27% in the NA1F+NA2F sum was achieved. Addition
of galactose alone up to a maximum concentration of 40 mM yielded a
maximum decrease of 12% in the NGA2F+NGA2F-GlcNac sum and a
corresponding 13% maximum increase in the NA1F+NA2F sum in a
concentration dependent manner.
[0133] The combined addition of galactose and manganese chloride to
production CDM GIA-1 resulted in a greater percent reduction in the
NGA2F+NGA2F-GlcNac sum and, correspondingly, a greater percent
increase in the NA1F+NA2F sum as compared to the addition of either
component alone (FIG. 24). For example, the addition of 40 .mu.M
manganese chloride alone reduced the NGA2F+NGA2F-GlcNac sum by 20%,
and the addition of 40 mM galactose alone decreased the
NGA2F+NGA2F-GlcNac sum by 12%. However, the combined addition of
manganese chloride and galactose at these same concentrations (i.e.
40 .mu.M manganese+40 mM galactose) led to a 27% decrease in the
NGA2F+NGA2F-GlcNac sum. The highest percentage decrease of 32% in
the NGA2F+NGA2F-GlcNac sum and the corresponding increase of 30% in
the NA1F+NA2F sum were observed for the culture supplemented with
20 .mu.M manganese chloride and 20 mM galactose.
6.8. Example 8
6.8.1. Materials & Methods
[0134] In the study summarized in this example, we investigated the
effects on product quality attributes resulting from the addition
of manganese chloride and/or galactose to chemically defined Life
Technologies Gibco GIA-1 media in a CHO cell line producing the
monoclonal antibody generically named mAb #2 in a fed-batch process
in 3 L bioreactors.
[0135] Growth and production media for the mAb #2 producing CHO
cell line were prepared using the proprietary Life Technologies
Gibco chemically defined media, GIA-1. Basal production and feed
media were supplemented with Manganese (II) Chloride (Sigma M3634)
and D(+)Galactose (Sigma G5388-1 kg) according to the experimental
design described in Table 9.
[0136] Upon thaw, cells were expanded in Corning vented non-baffled
shake flasks maintained on orbital shakers at 140 RPM, and in 10 L
cell bags (2 L working volume) maintained at 25 RPM, 7.degree.
angle, 0.25 SLPM airflow in a dry incubator at 36.degree. C. and 5%
CO2. Production cultures were initiated in 3 L bioreactors (1.5 L
initial working volume) at 36.degree. C., 25% dissolved oxygen, 200
RPM, and pH 7.0. The chemically-defined feed from Life Technologies
Gibco JCL-5 was added as follows: 3% (v/v)--day 3, 5%--day 5,
7%--day 7, 10%--day 9, and 10%--day 11. Additional 400 g/L glucose
was added to the bioreactor cultures as needed to ensure the
glucose levels did not deplete. Bioreactors were harvested at
viability of approximately 70% or below or on production day 15,
whichever condition occurred first.
6.8.2. Experimental Design
[0137] As detailed in Table 9, manganese chloride was supplemented
at the following concentrations in both production and feed media:
0, 25, 50, and 75 .mu.M. Galactose was supplemented at 0, 15, 30,
and 60 mM concentrations in both production and feed media. In
addition, a combined manganese chloride and galactose
supplementation strategy was utilized for the production basal and
feed media at 25 .mu.M manganese chloride+15 mM galactose, and 50
.mu.M manganese chloride+30 mM galactose. Basal and feed media for
the control cultures were not supplemented with manganese chloride
or galactose.
TABLE-US-00009 TABLE 9 Experimental design for Example 8 Manganese
Galactose (.mu.M) (mM) ID 0 0 Mn(0) Gal(0) 25 0 Mn(25) Gal(0) 50 0
Mn(50) Gal(0) 75 0 Mn(75) Gal(0) 0 15 Mn(0) Gal(15) 0 30 Mn(0)
Gal(30) 0 60 Mn(0) Gal(60) 25 15 Mn(25) Gal(15) 50 30 Mn(50)
Gal(30)
6.8.3. Culture Growth & Productivity
[0138] Growth profiles of most cultures supplemented with galactose
in the 0 to 60 mM concentration range and/or manganese chloride in
the 0 to 75 .mu.M range were comparable to the control culture
except for the culture supplemented with 25 .mu.M manganese
chloride alone which grew slower after production day 7 (FIG. 25A).
However, increasing the amount of manganese chloride supplemented
to production CDM GIA-1 to 50 .mu.M or 75 .mu.M resulted in
cultures with growth profiles comparable to the control culture.
Viability profiles and harvest titer were comparable to the control
condition (FIGS. 25B, 25C).
6.8.4. Oligosaccharide Analysis
[0139] In this example, the modulation of galactosylation with the
addition of manganese chloride and/or galactose to chemically
defined media GIA-1 was explored using a CHO cell line producing
the monoclonal antibody mAb #2.
[0140] The addition of manganese chloride alone in the range of 0
to 75 .mu.M to production CDM GIA-1 decreased the
NGA2F+NGA2F-GlcNAc sum by a maximum of 18% (FIG. 26). A comparable
maximum increase of 16% in the NA1F+NA2F sum was achieved. Addition
of galactose alone up to a maximum concentration of 60 mM yielded a
maximum decrease of 12% in the NGA2F+NGA2F-GlcNAc sum and a
corresponding 11% maximum increase in the NA1F+NA2F sum.
[0141] When manganese chloride and galactose were supplemented
together into the basal and feed media, the results demonstrated at
least an additive effect and sometimes a synergistic effect towards
the decrease in the NGA2F+NGA2F-GlcNAc and the increase in the
NA1F+NA2F oligosaccharides (FIG. 27). The synergistic effect was
observed for the condition supplemented with 25 .mu.M manganese
chloride and 15 mM galactose. The observed 22% decrease in the
NGA2F+NGA2F-GlcNAc sum was 5% more than the sum of the decrease
observed with the addition of 25 .mu.M manganese chloride alone
(10%) and 15 mM galactose alone (7%). The additive effect was
observed for the condition supplemented with 50 .mu.M manganese
chloride and 30 mM galactose. The observed 28% decrease in the
NGA2F+NGA2F-GlcNAc sum was comparable to the sum of the decrease
observed with the addition of 50 .mu.M manganese chloride alone
(18%) and 30 mM galactose alone (12%). A maximum decrease of 28% in
the NGA2F+NGA2F-GlcNAc and a corresponding 25% maximum increase in
the NA1F+NA2F sum compared to the control condition was observed
with the combined addition of 50 .mu.M manganese chloride and 30 mM
galactose to chemically defined GIA-1 media.
[0142] All patents, patent applications, publications, product
descriptions and protocols, cited in this specification are hereby
incorporated by reference in their entirety. In case of a conflict
in terminology, the present disclosure controls.
[0143] While it will be apparent that the invention herein
described is well calculated to achieve the benefits and advantages
set forth above, the present invention is not to be limited in
scope by the specific embodiments described herein. It will be
appreciated that the invention is susceptible to modification,
variation and change without departing from the spirit thereof.
* * * * *